Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Amino acid sequence diversity of the major human papillomavirus capsid protein: Implications for current and next generation vaccines<sup><xref ref-type="fn" rid="d32e1209">☆</xref></sup></title><author><name sortKey="Ahmed, Amina I" sort="Ahmed, Amina I" uniqKey="Ahmed A" first="Amina I." last="Ahmed">Amina I. Ahmed</name></author><author><name sortKey="Bissett, Sara L" sort="Bissett, Sara L" uniqKey="Bissett S" first="Sara L." last="Bissett">Sara L. Bissett</name></author><author><name sortKey="Beddows, Simon" sort="Beddows, Simon" uniqKey="Beddows S" first="Simon" last="Beddows">Simon Beddows</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23722024</idno><idno type="pmc">3769806</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769806</idno><idno type="RBID">PMC:3769806</idno><idno type="doi">10.1016/j.meegid.2013.05.013</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">000119</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000119</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Amino acid sequence diversity of the major human papillomavirus capsid protein: Implications for current and next generation vaccines<sup><xref ref-type="fn" rid="d32e1209">☆</xref></sup></title><author><name sortKey="Ahmed, Amina I" sort="Ahmed, Amina I" uniqKey="Ahmed A" first="Amina I." last="Ahmed">Amina I. Ahmed</name></author><author><name sortKey="Bissett, Sara L" sort="Bissett, Sara L" uniqKey="Bissett S" first="Sara L." last="Bissett">Sara L. Bissett</name></author><author><name sortKey="Beddows, Simon" sort="Beddows, Simon" uniqKey="Beddows S" first="Simon" last="Beddows">Simon Beddows</name></author></analytic><series><title level="j">Infection, Genetics and Evolution</title><idno type="ISSN">1567-1348</idno><idno type="eISSN">1567-7257</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Highlights</title><p><list list-type="simple"><list-item id="o0005"><label>•</label><p>We evaluated amino acid diversity of the major capsid protein of HPV.</p></list-item><list-item id="o0010"><label>•</label><p>Residues displaying high entropy were found within surface-exposed domains.</p></list-item><list-item id="o0015"><label>•</label><p>We discuss the implications of this diversity on the current and next generation HPV vaccines.</p></list-item></list></p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Arbyn, M" uniqKey="Arbyn M">M. Arbyn</name></author><author><name sortKey="Castellsague, X" uniqKey="Castellsague X">X. Castellsague</name></author><author><name sortKey="De Sanjose, S" uniqKey="De Sanjose S">S. de Sanjose</name></author><author><name sortKey="Bruni, L" uniqKey="Bruni L">L. Bruni</name></author><author><name sortKey="Saraiya, M" uniqKey="Saraiya M">M. Saraiya</name></author><author><name sortKey="Bray, F" uniqKey="Bray F">F. Bray</name></author><author><name sortKey="Ferlay, J" uniqKey="Ferlay J">J. Ferlay</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bernard, H U" uniqKey="Bernard H">H.U. Bernard</name></author><author><name sortKey="Calleja Macias, I E" uniqKey="Calleja Macias I">I.E. Calleja-Macias</name></author><author><name sortKey="Dunn, S T" uniqKey="Dunn S">S.T. Dunn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bishop, B" uniqKey="Bishop B">B. Bishop</name></author><author><name sortKey="Dasgupta, J" uniqKey="Dasgupta J">J. Dasgupta</name></author><author><name sortKey="Klein, M" uniqKey="Klein M">M. Klein</name></author><author><name sortKey="Garcea, R L" uniqKey="Garcea R">R.L. Garcea</name></author><author><name sortKey="Christensen, N D" uniqKey="Christensen N">N.D. Christensen</name></author><author><name sortKey="Zhao, R" uniqKey="Zhao R">R. Zhao</name></author><author><name sortKey="Chen, X S" uniqKey="Chen X">X.S. Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brendle, S A" uniqKey="Brendle S">S.A. Brendle</name></author><author><name sortKey="Culp, T D" uniqKey="Culp T">T.D. Culp</name></author><author><name sortKey="Broutian, T R" uniqKey="Broutian T">T.R. Broutian</name></author><author><name sortKey="Christensen, N D" uniqKey="Christensen N">N.D. Christensen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Buck, C B" uniqKey="Buck C">C.B. Buck</name></author><author><name sortKey="Cheng, N" uniqKey="Cheng N">N. Cheng</name></author><author><name sortKey="Thompson, C D" uniqKey="Thompson C">C.D. Thompson</name></author><author><name sortKey="Lowy, D R" uniqKey="Lowy D">D.R. Lowy</name></author><author><name sortKey="Steven, A C" uniqKey="Steven A">A.C. Steven</name></author><author><name sortKey="Schiller, J T" uniqKey="Schiller J">J.T. Schiller</name></author><author><name sortKey="Trus, B L" uniqKey="Trus B">B.L. Trus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Caparros Wanderley, W" uniqKey="Caparros Wanderley W">W. Caparros-Wanderley</name></author><author><name sortKey="Savage, N" uniqKey="Savage N">N. Savage</name></author><author><name sortKey="Hill Perkins, M" uniqKey="Hill Perkins M">M. Hill-Perkins</name></author><author><name sortKey="Layton, G" uniqKey="Layton G">G. Layton</name></author><author><name sortKey="Weber, J" uniqKey="Weber J">J. Weber</name></author><author><name sortKey="Davies, D H" uniqKey="Davies D">D.H. Davies</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carpentier, G S" uniqKey="Carpentier G">G.S. Carpentier</name></author><author><name sortKey="Fleury, M J" uniqKey="Fleury M">M.J. Fleury</name></author><author><name sortKey="Touze, A" uniqKey="Touze A">A. Touze</name></author><author><name sortKey="Sadeyen, J R" uniqKey="Sadeyen J">J.R. Sadeyen</name></author><author><name sortKey="Tourne, S" uniqKey="Tourne S">S. Tourne</name></author><author><name sortKey="Sizaret, P Y" uniqKey="Sizaret P">P.Y. Sizaret</name></author><author><name sortKey="Coursaget, P" uniqKey="Coursaget P">P. Coursaget</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carter, J J" uniqKey="Carter J">J.J. Carter</name></author><author><name sortKey="Koutsky, L A" uniqKey="Koutsky L">L.A. Koutsky</name></author><author><name sortKey="Hughes, J P" uniqKey="Hughes J">J.P. Hughes</name></author><author><name sortKey="Lee, S K" uniqKey="Lee S">S.K. Lee</name></author><author><name sortKey="Kuypers, J" uniqKey="Kuypers J">J. Kuypers</name></author><author><name sortKey="Kiviat, N" uniqKey="Kiviat N">N. Kiviat</name></author><author><name sortKey="Galloway, D A" uniqKey="Galloway D">D.A. Galloway</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carter, J J" uniqKey="Carter J">J.J. Carter</name></author><author><name sortKey="Wipf, G C" uniqKey="Wipf G">G.C. Wipf</name></author><author><name sortKey="Benki, S F" uniqKey="Benki S">S.F. Benki</name></author><author><name sortKey="Christensen, N D" uniqKey="Christensen N">N.D. Christensen</name></author><author><name sortKey="Galloway, D A" uniqKey="Galloway D">D.A. Galloway</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carter, J J" uniqKey="Carter J">J.J. Carter</name></author><author><name sortKey="Wipf, G C" uniqKey="Wipf G">G.C. Wipf</name></author><author><name sortKey="Madeleine, M M" uniqKey="Madeleine M">M.M. Madeleine</name></author><author><name sortKey="Schwartz, S M" uniqKey="Schwartz S">S.M. Schwartz</name></author><author><name sortKey="Koutsky, L A" uniqKey="Koutsky L">L.A. Koutsky</name></author><author><name sortKey="Galloway, D A" uniqKey="Galloway D">D.A. Galloway</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, X S" uniqKey="Chen X">X.S. Chen</name></author><author><name sortKey="Garcea, R L" uniqKey="Garcea R">R.L. Garcea</name></author><author><name sortKey="Goldberg, I" uniqKey="Goldberg I">I. Goldberg</name></author><author><name sortKey="Casini, G" uniqKey="Casini G">G. Casini</name></author><author><name sortKey="Harrison, S C" uniqKey="Harrison S">S.C. Harrison</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, Z" uniqKey="Chen Z">Z. Chen</name></author><author><name sortKey="Desalle, R" uniqKey="Desalle R">R. DeSalle</name></author><author><name sortKey="Schiffman, M" uniqKey="Schiffman M">M. Schiffman</name></author><author><name sortKey="Herrero, R" uniqKey="Herrero R">R. Herrero</name></author><author><name sortKey="Burk, R D" uniqKey="Burk R">R.D. Burk</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, Z" uniqKey="Chen Z">Z. Chen</name></author><author><name sortKey="Schiffman, M" uniqKey="Schiffman M">M. Schiffman</name></author><author><name sortKey="Herrero, R" uniqKey="Herrero R">R. Herrero</name></author><author><name sortKey="Desalle, R" uniqKey="Desalle R">R. Desalle</name></author><author><name sortKey="Anastos, K" uniqKey="Anastos K">K. Anastos</name></author><author><name sortKey="Segondy, M" uniqKey="Segondy M">M. Segondy</name></author><author><name sortKey="Sahasrabuddhe, V V" uniqKey="Sahasrabuddhe V">V.V. Sahasrabuddhe</name></author><author><name sortKey="Gravitt, P E" uniqKey="Gravitt P">P.E. Gravitt</name></author><author><name sortKey="Hsing, A W" uniqKey="Hsing A">A.W. Hsing</name></author><author><name sortKey="Burk, R D" uniqKey="Burk R">R.D. Burk</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cheng, G" uniqKey="Cheng G">G. Cheng</name></author><author><name sortKey="Icenogle, J P" uniqKey="Icenogle J">J.P. Icenogle</name></author><author><name sortKey="Kirnbauer, R" uniqKey="Kirnbauer R">R. Kirnbauer</name></author><author><name sortKey="Hubbert, N L" uniqKey="Hubbert N">N.L. Hubbert</name></author><author><name sortKey="St Louis, M E" uniqKey="St Louis M">M.E. St Louis</name></author><author><name sortKey="Han, C" uniqKey="Han C">C. Han</name></author><author><name sortKey="Svare, E I" uniqKey="Svare E">E.I. Svare</name></author><author><name sortKey="Kjaer, S K" uniqKey="Kjaer S">S.K. Kjaer</name></author><author><name sortKey="Lowy, D R" uniqKey="Lowy D">D.R. Lowy</name></author><author><name sortKey="Schiller, J T" uniqKey="Schiller J">J.T. Schiller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Villiers, E M" uniqKey="De Villiers E">E.M. de Villiers</name></author><author><name sortKey="Fauquet, C" uniqKey="Fauquet C">C. Fauquet</name></author><author><name sortKey="Broker, T R" uniqKey="Broker T">T.R. Broker</name></author><author><name sortKey="Bernard, H U" uniqKey="Bernard H">H.U. Bernard</name></author><author><name sortKey="Zur Hausen, H" uniqKey="Zur Hausen H">H. zur Hausen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Deschuyteneer, M" uniqKey="Deschuyteneer M">M. Deschuyteneer</name></author><author><name sortKey="Elouahabi, A" uniqKey="Elouahabi A">A. Elouahabi</name></author><author><name sortKey="Plainchamp, D" uniqKey="Plainchamp D">D. Plainchamp</name></author><author><name sortKey="Plisnier, M" uniqKey="Plisnier M">M. Plisnier</name></author><author><name sortKey="Soete, D" uniqKey="Soete D">D. Soete</name></author><author><name sortKey="Corazza, Y" uniqKey="Corazza Y">Y. Corazza</name></author><author><name sortKey="Lockman, L" uniqKey="Lockman L">L. Lockman</name></author><author><name sortKey="Giannini, S" uniqKey="Giannini S">S. Giannini</name></author><author><name sortKey="Deschamps, M" uniqKey="Deschamps M">M. Deschamps</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dias, D" uniqKey="Dias D">D. Dias</name></author><author><name sortKey="Van Doren, J" uniqKey="Van Doren J">J. Van Doren</name></author><author><name sortKey="Schlottmann, S" uniqKey="Schlottmann S">S. Schlottmann</name></author><author><name sortKey="Kelly, S" uniqKey="Kelly S">S. Kelly</name></author><author><name sortKey="Puchalski, D" uniqKey="Puchalski D">D. Puchalski</name></author><author><name sortKey="Ruiz, W" uniqKey="Ruiz W">W. Ruiz</name></author><author><name sortKey="Boerckel, P" uniqKey="Boerckel P">P. Boerckel</name></author><author><name sortKey="Kessler, J" uniqKey="Kessler J">J. Kessler</name></author><author><name sortKey="Antonello, J M" uniqKey="Antonello J">J.M. Antonello</name></author><author><name sortKey="Green, T" uniqKey="Green T">T. Green</name></author><author><name sortKey="Brown, M" uniqKey="Brown M">M. Brown</name></author><author><name sortKey="Smith, J" uniqKey="Smith J">J. Smith</name></author><author><name sortKey="Chirmule, N" uniqKey="Chirmule N">N. Chirmule</name></author><author><name sortKey="Barr, E" uniqKey="Barr E">E. Barr</name></author><author><name sortKey="Jansen, K U" uniqKey="Jansen K">K.U. Jansen</name></author><author><name sortKey="Esser, M T" uniqKey="Esser M">M.T. Esser</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Draper, E" uniqKey="Draper E">E. Draper</name></author><author><name sortKey="Bissett, S L" uniqKey="Bissett S">S.L. Bissett</name></author><author><name sortKey="Howell Jones, R" uniqKey="Howell Jones R">R. Howell-Jones</name></author><author><name sortKey="Edwards, D" uniqKey="Edwards D">D. Edwards</name></author><author><name sortKey="Munslow, G" uniqKey="Munslow G">G. Munslow</name></author><author><name sortKey="Soldan, K" uniqKey="Soldan K">K. Soldan</name></author><author><name sortKey="Beddows, S" uniqKey="Beddows S">S. Beddows</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Einstein, M H" uniqKey="Einstein M">M.H. Einstein</name></author><author><name sortKey="Baron, M" uniqKey="Baron M">M. Baron</name></author><author><name sortKey="Levin, M J" uniqKey="Levin M">M.J. Levin</name></author><author><name sortKey="Chatterjee, A" uniqKey="Chatterjee A">A. Chatterjee</name></author><author><name sortKey="Edwards, R P" uniqKey="Edwards R">R.P. Edwards</name></author><author><name sortKey="Zepp, F" uniqKey="Zepp F">F. Zepp</name></author><author><name sortKey="Carletti, I" uniqKey="Carletti I">I. Carletti</name></author><author><name sortKey="Dessy, F J" uniqKey="Dessy F">F.J. Dessy</name></author><author><name sortKey="Trofa, A F" uniqKey="Trofa A">A.F. Trofa</name></author><author><name sortKey="Schuind, A" uniqKey="Schuind A">A. Schuind</name></author><author><name sortKey="Dubin, G" uniqKey="Dubin G">G. Dubin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Einstein, M H" uniqKey="Einstein M">M.H. Einstein</name></author><author><name sortKey="Baron, M" uniqKey="Baron M">M. Baron</name></author><author><name sortKey="Levin, M J" uniqKey="Levin M">M.J. Levin</name></author><author><name sortKey="Chatterjee, A" uniqKey="Chatterjee A">A. Chatterjee</name></author><author><name sortKey="Fox, B" uniqKey="Fox B">B. Fox</name></author><author><name sortKey="Scholar, S" uniqKey="Scholar S">S. Scholar</name></author><author><name sortKey="Rosen, J" uniqKey="Rosen J">J. Rosen</name></author><author><name sortKey="Chakhtoura, N" uniqKey="Chakhtoura N">N. Chakhtoura</name></author><author><name sortKey="Lebacq, M" uniqKey="Lebacq M">M. Lebacq</name></author><author><name sortKey="Van Der Most, R" uniqKey="Van Der Most R">R. van der Most</name></author><author><name sortKey="Moris, P" uniqKey="Moris P">P. Moris</name></author><author><name sortKey="Giannini, S L" uniqKey="Giannini S">S.L. Giannini</name></author><author><name sortKey="Schuind, A" uniqKey="Schuind A">A. Schuind</name></author><author><name sortKey="Datta, S K" uniqKey="Datta S">S.K. Datta</name></author><author><name sortKey="Descamps, D" uniqKey="Descamps D">D. Descamps</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fleury, M J" uniqKey="Fleury M">M.J. Fleury</name></author><author><name sortKey="Touze, A" uniqKey="Touze A">A. Touze</name></author><author><name sortKey="Maurel, M C" uniqKey="Maurel M">M.C. Maurel</name></author><author><name sortKey="Moreau, T" uniqKey="Moreau T">T. Moreau</name></author><author><name sortKey="Coursaget, P" uniqKey="Coursaget P">P. Coursaget</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Giannini, S L" uniqKey="Giannini S">S.L. Giannini</name></author><author><name sortKey="Hanon, E" uniqKey="Hanon E">E. Hanon</name></author><author><name sortKey="Moris, P" uniqKey="Moris P">P. Moris</name></author><author><name sortKey="Van Mechelen, M" uniqKey="Van Mechelen M">M. Van Mechelen</name></author><author><name sortKey="Morel, S" uniqKey="Morel S">S. Morel</name></author><author><name sortKey="Dessy, F" uniqKey="Dessy F">F. Dessy</name></author><author><name sortKey="Fourneau, M A" uniqKey="Fourneau M">M.A. Fourneau</name></author><author><name sortKey="Colau, B" uniqKey="Colau B">B. Colau</name></author><author><name sortKey="Suzich, J" uniqKey="Suzich J">J. Suzich</name></author><author><name sortKey="Losonksy, G" uniqKey="Losonksy G">G. Losonksy</name></author><author><name sortKey="Martin, M T" uniqKey="Martin M">M.T. Martin</name></author><author><name sortKey="Dubin, G" uniqKey="Dubin G">G. Dubin</name></author><author><name sortKey="Wettendorff, M A" uniqKey="Wettendorff M">M.A. Wettendorff</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Guex, N" uniqKey="Guex N">N. Guex</name></author><author><name sortKey="Peitsch, M C" uniqKey="Peitsch M">M.C. Peitsch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Huang, J W" uniqKey="Huang J">J.W. Huang</name></author><author><name sortKey="Lin, W F" uniqKey="Lin W">W.F. Lin</name></author><author><name sortKey="Yang, J M" uniqKey="Yang J">J.M. Yang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jin, M" uniqKey="Jin M">M. Jin</name></author><author><name sortKey="Chen, J" uniqKey="Chen J">J. Chen</name></author><author><name sortKey="Zhang, X H" uniqKey="Zhang X">X.H. Zhang</name></author><author><name sortKey="Zhang, M" uniqKey="Zhang M">M. Zhang</name></author><author><name sortKey="Li, H Y" uniqKey="Li H">H.Y. Li</name></author><author><name sortKey="Cheng, W X" uniqKey="Cheng W">W.X. Cheng</name></author><author><name sortKey="Liu, N" uniqKey="Liu N">N. Liu</name></author><author><name sortKey="Tan, M" uniqKey="Tan M">M. Tan</name></author><author><name sortKey="Jiang, T" uniqKey="Jiang T">T. Jiang</name></author><author><name sortKey="Duan, Z J" uniqKey="Duan Z">Z.J. Duan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kemp, T J" uniqKey="Kemp T">T.J. Kemp</name></author><author><name sortKey="Hildesheim, A" uniqKey="Hildesheim A">A. Hildesheim</name></author><author><name sortKey="Safaeian, M" uniqKey="Safaeian M">M. Safaeian</name></author><author><name sortKey="Dauner, J G" uniqKey="Dauner J">J.G. Dauner</name></author><author><name sortKey="Pan, Y" uniqKey="Pan Y">Y. Pan</name></author><author><name sortKey="Porras, C" uniqKey="Porras C">C. Porras</name></author><author><name sortKey="Schiller, J T" uniqKey="Schiller J">J.T. Schiller</name></author><author><name sortKey="Lowy, D R" uniqKey="Lowy D">D.R. Lowy</name></author><author><name sortKey="Herrero, R" uniqKey="Herrero R">R. Herrero</name></author><author><name sortKey="Pinto, L A" uniqKey="Pinto L">L.A. Pinto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Knappe, M" uniqKey="Knappe M">M. Knappe</name></author><author><name sortKey="Bodevin, S" uniqKey="Bodevin S">S. Bodevin</name></author><author><name sortKey="Selinka, H C" uniqKey="Selinka H">H.C. Selinka</name></author><author><name sortKey="Spillmann, D" uniqKey="Spillmann D">D. Spillmann</name></author><author><name sortKey="Streeck, R E" uniqKey="Streeck R">R.E. Streeck</name></author><author><name sortKey="Chen, X S" uniqKey="Chen X">X.S. Chen</name></author><author><name sortKey="Lindahl, U" uniqKey="Lindahl U">U. Lindahl</name></author><author><name sortKey="Sapp, M" uniqKey="Sapp M">M. Sapp</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Korber, B T" uniqKey="Korber B">B.T. Korber</name></author><author><name sortKey="Kunstman, K J" uniqKey="Kunstman K">K.J. Kunstman</name></author><author><name sortKey="Patterson, B K" uniqKey="Patterson B">B.K. Patterson</name></author><author><name sortKey="Furtado, M" uniqKey="Furtado M">M. Furtado</name></author><author><name sortKey="Mcevilly, M M" uniqKey="Mcevilly M">M.M. McEvilly</name></author><author><name sortKey="Levy, R" uniqKey="Levy R">R. Levy</name></author><author><name sortKey="Wolinsky, S M" uniqKey="Wolinsky S">S.M. Wolinsky</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, N" uniqKey="Li N">N. Li</name></author><author><name sortKey="Franceschi, S" uniqKey="Franceschi S">S. Franceschi</name></author><author><name sortKey="Howell Jones, R" uniqKey="Howell Jones R">R. Howell-Jones</name></author><author><name sortKey="Snijders, P J" uniqKey="Snijders P">P.J. Snijders</name></author><author><name sortKey="Clifford, G M" uniqKey="Clifford G">G.M. Clifford</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lin, S W" uniqKey="Lin S">S.W. Lin</name></author><author><name sortKey="Ghosh, A" uniqKey="Ghosh A">A. Ghosh</name></author><author><name sortKey="Porras, C" uniqKey="Porras C">C. Porras</name></author><author><name sortKey="Markt, S C" uniqKey="Markt S">S.C. Markt</name></author><author><name sortKey="Rodriguez, A C" uniqKey="Rodriguez A">A.C. Rodriguez</name></author><author><name sortKey="Schiffman, M" uniqKey="Schiffman M">M. Schiffman</name></author><author><name sortKey="Wacholder, S" uniqKey="Wacholder S">S. Wacholder</name></author><author><name sortKey="Kemp, T J" uniqKey="Kemp T">T.J. Kemp</name></author><author><name sortKey="Pinto, L A" uniqKey="Pinto L">L.A. Pinto</name></author><author><name sortKey="Gonzalez, P" uniqKey="Gonzalez P">P. Gonzalez</name></author><author><name sortKey="Wentzensen, N" uniqKey="Wentzensen N">N. Wentzensen</name></author><author><name sortKey="Esser, M T" uniqKey="Esser M">M.T. Esser</name></author><author><name sortKey="Matys, K" uniqKey="Matys K">K. Matys</name></author><author><name sortKey="Meuree, A" uniqKey="Meuree A">A. Meuree</name></author><author><name sortKey="Quint, W" uniqKey="Quint W">W. Quint</name></author><author><name sortKey="Van Doorn, L J" uniqKey="Van Doorn L">L.J. van Doorn</name></author><author><name sortKey="Herrero, R" uniqKey="Herrero R">R. Herrero</name></author><author><name sortKey="Hildesheim, A" uniqKey="Hildesheim A">A. Hildesheim</name></author><author><name sortKey="Safaeian, M" uniqKey="Safaeian M">M. Safaeian</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Longet, S" uniqKey="Longet S">S. Longet</name></author><author><name sortKey="Schiller, J T" uniqKey="Schiller J">J.T. Schiller</name></author><author><name sortKey="Bobst, M" uniqKey="Bobst M">M. Bobst</name></author><author><name sortKey="Jichlinski, P" uniqKey="Jichlinski P">P. Jichlinski</name></author><author><name sortKey="Nardelli Haefliger, D" uniqKey="Nardelli Haefliger D">D. Nardelli-Haefliger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lu, B" uniqKey="Lu B">B. Lu</name></author><author><name sortKey="Kumar, A" uniqKey="Kumar A">A. Kumar</name></author><author><name sortKey="Castellsague, X" uniqKey="Castellsague X">X. Castellsague</name></author><author><name sortKey="Giuliano, A R" uniqKey="Giuliano A">A.R. Giuliano</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ludmerer, S W" uniqKey="Ludmerer S">S.W. Ludmerer</name></author><author><name sortKey="Benincasa, D" uniqKey="Benincasa D">D. Benincasa</name></author><author><name sortKey="Mark, G E" uniqKey="Mark G">G.E. Mark</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mcclements, W L" uniqKey="Mcclements W">W.L. McClements</name></author><author><name sortKey="Wang, X M" uniqKey="Wang X">X.M. Wang</name></author><author><name sortKey="Ling, J C" uniqKey="Ling J">J.C. Ling</name></author><author><name sortKey="Skulsky, D M" uniqKey="Skulsky D">D.M. Skulsky</name></author><author><name sortKey="Christensen, N D" uniqKey="Christensen N">N.D. Christensen</name></author><author><name sortKey="Jansen, K U" uniqKey="Jansen K">K.U. Jansen</name></author><author><name sortKey="Ludmerer, S W" uniqKey="Ludmerer S">S.W. Ludmerer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Munoz, N" uniqKey="Munoz N">N. Munoz</name></author><author><name sortKey="Kjaer, S K" uniqKey="Kjaer S">S.K. Kjaer</name></author><author><name sortKey="Sigurdsson, K" uniqKey="Sigurdsson K">K. Sigurdsson</name></author><author><name sortKey="Iversen, O E" uniqKey="Iversen O">O.E. Iversen</name></author><author><name sortKey="Hernandez Avila, M" uniqKey="Hernandez Avila M">M. Hernandez-Avila</name></author><author><name sortKey="Wheeler, C M" uniqKey="Wheeler C">C.M. Wheeler</name></author><author><name sortKey="Perez, G" uniqKey="Perez G">G. Perez</name></author><author><name sortKey="Brown, D R" uniqKey="Brown D">D.R. Brown</name></author><author><name sortKey="Koutsky, L A" uniqKey="Koutsky L">L.A. Koutsky</name></author><author><name sortKey="Tay, E H" uniqKey="Tay E">E.H. Tay</name></author><author><name sortKey="Garcia, P J" uniqKey="Garcia P">P.J. Garcia</name></author><author><name sortKey="Ault, K A" uniqKey="Ault K">K.A. Ault</name></author><author><name sortKey="Garland, S M" uniqKey="Garland S">S.M. Garland</name></author><author><name sortKey="Leodolter, S" uniqKey="Leodolter S">S. Leodolter</name></author><author><name sortKey="Olsson, S E" uniqKey="Olsson S">S.E. Olsson</name></author><author><name sortKey="Tang, G W" uniqKey="Tang G">G.W. Tang</name></author><author><name sortKey="Ferris, D G" uniqKey="Ferris D">D.G. Ferris</name></author><author><name sortKey="Paavonen, J" uniqKey="Paavonen J">J. Paavonen</name></author><author><name sortKey="Steben, M" uniqKey="Steben M">M. Steben</name></author><author><name sortKey="Bosch, F X" uniqKey="Bosch F">F.X. Bosch</name></author><author><name sortKey="Dillner, J" uniqKey="Dillner J">J. Dillner</name></author><author><name sortKey="Huh, W K" uniqKey="Huh W">W.K. Huh</name></author><author><name sortKey="Joura, E A" uniqKey="Joura E">E.A. Joura</name></author><author><name sortKey="Kurman, R J" uniqKey="Kurman R">R.J. Kurman</name></author><author><name sortKey="Majewski, S" uniqKey="Majewski S">S. Majewski</name></author><author><name sortKey="Myers, E R" uniqKey="Myers E">E.R. Myers</name></author><author><name sortKey="Villa, L L" uniqKey="Villa L">L.L. Villa</name></author><author><name sortKey="Taddeo, F J" uniqKey="Taddeo F">F.J. Taddeo</name></author><author><name sortKey="Roberts, C" uniqKey="Roberts C">C. Roberts</name></author><author><name sortKey="Tadesse, A" uniqKey="Tadesse A">A. Tadesse</name></author><author><name sortKey="Bryan, J T" uniqKey="Bryan J">J.T. Bryan</name></author><author><name sortKey="Lupinacci, L C" uniqKey="Lupinacci L">L.C. Lupinacci</name></author><author><name sortKey="Giacoletti, K E" uniqKey="Giacoletti K">K.E. Giacoletti</name></author><author><name sortKey="Sings, H L" uniqKey="Sings H">H.L. Sings</name></author><author><name sortKey="James, M K" uniqKey="James M">M.K. James</name></author><author><name sortKey="Hesley, T M" uniqKey="Hesley T">T.M. Hesley</name></author><author><name sortKey="Barr, E" uniqKey="Barr E">E. Barr</name></author><author><name sortKey="Haupt, R M" uniqKey="Haupt R">R.M. Haupt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Myers, G" uniqKey="Myers G">G. Myers</name></author><author><name sortKey="Delius, H" uniqKey="Delius H">H. Delius</name></author><author><name sortKey="Icenogle, J" uniqKey="Icenogle J">J. Icenogle</name></author><author><name sortKey="Bernard, H U" uniqKey="Bernard H">H.U. Bernard</name></author><author><name sortKey="Baker, C" uniqKey="Baker C">C. Baker</name></author><author><name sortKey="Halpern, A" uniqKey="Halpern A">A. Halpern</name></author><author><name sortKey="Wheeler, C" uniqKey="Wheeler C">C. Wheeler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Orozco, J J" uniqKey="Orozco J">J.J. Orozco</name></author><author><name sortKey="Carter, J J" uniqKey="Carter J">J.J. Carter</name></author><author><name sortKey="Koutsky, L A" uniqKey="Koutsky L">L.A. Koutsky</name></author><author><name sortKey="Galloway, D A" uniqKey="Galloway D">D.A. Galloway</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Paavonen, J" uniqKey="Paavonen J">J. Paavonen</name></author><author><name sortKey="Jenkins, D" uniqKey="Jenkins D">D. Jenkins</name></author><author><name sortKey="Bosch, F X" uniqKey="Bosch F">F.X. Bosch</name></author><author><name sortKey="Naud, P" uniqKey="Naud P">P. Naud</name></author><author><name sortKey="Salmeron, J" uniqKey="Salmeron J">J. Salmeron</name></author><author><name sortKey="Wheeler, C M" uniqKey="Wheeler C">C.M. Wheeler</name></author><author><name sortKey="Chow, S N" uniqKey="Chow S">S.N. Chow</name></author><author><name sortKey="Apter, D L" uniqKey="Apter D">D.L. Apter</name></author><author><name sortKey="Kitchener, H C" uniqKey="Kitchener H">H.C. Kitchener</name></author><author><name sortKey="Castellsague, X" uniqKey="Castellsague X">X. Castellsague</name></author><author><name sortKey="De Carvalho, N S" uniqKey="De Carvalho N">N.S. de Carvalho</name></author><author><name sortKey="Skinner, S R" uniqKey="Skinner S">S.R. Skinner</name></author><author><name sortKey="Harper, D M" uniqKey="Harper D">D.M. Harper</name></author><author><name sortKey="Hedrick, J A" uniqKey="Hedrick J">J.A. Hedrick</name></author><author><name sortKey="Jaisamrarn, U" uniqKey="Jaisamrarn U">U. Jaisamrarn</name></author><author><name sortKey="Limson, G A" uniqKey="Limson G">G.A. Limson</name></author><author><name sortKey="Dionne, M" uniqKey="Dionne M">M. Dionne</name></author><author><name sortKey="Quint, W" uniqKey="Quint W">W. Quint</name></author><author><name sortKey="Spiessens, B" uniqKey="Spiessens B">B. Spiessens</name></author><author><name sortKey="Peeters, P" uniqKey="Peeters P">P. Peeters</name></author><author><name sortKey="Struyf, F" uniqKey="Struyf F">F. Struyf</name></author><author><name sortKey="Wieting, S L" uniqKey="Wieting S">S.L. Wieting</name></author><author><name sortKey="Lehtinen, M O" uniqKey="Lehtinen M">M.O. Lehtinen</name></author><author><name sortKey="Dubin, G" uniqKey="Dubin G">G. Dubin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pastrana, D V" uniqKey="Pastrana D">D.V. Pastrana</name></author><author><name sortKey="Buck, C B" uniqKey="Buck C">C.B. Buck</name></author><author><name sortKey="Pang, Y Y" uniqKey="Pang Y">Y.Y. Pang</name></author><author><name sortKey="Thompson, C D" uniqKey="Thompson C">C.D. Thompson</name></author><author><name sortKey="Castle, P E" uniqKey="Castle P">P.E. Castle</name></author><author><name sortKey="Fitzgerald, P C" uniqKey="Fitzgerald P">P.C. FitzGerald</name></author><author><name sortKey="Kruger Kjaer, S" uniqKey="Kruger Kjaer S">S. Kruger Kjaer</name></author><author><name sortKey="Lowy, D R" uniqKey="Lowy D">D.R. Lowy</name></author><author><name sortKey="Schiller, J T" uniqKey="Schiller J">J.T. Schiller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pastrana, D V" uniqKey="Pastrana D">D.V. Pastrana</name></author><author><name sortKey="Vass, W C" uniqKey="Vass W">W.C. Vass</name></author><author><name sortKey="Lowy, D R" uniqKey="Lowy D">D.R. Lowy</name></author><author><name sortKey="Schiller, J T" uniqKey="Schiller J">J.T. Schiller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rhee, S Y" uniqKey="Rhee S">S.Y. Rhee</name></author><author><name sortKey="Liu, T F" uniqKey="Liu T">T.F. Liu</name></author><author><name sortKey="Kiuchi, M" uniqKey="Kiuchi M">M. Kiuchi</name></author><author><name sortKey="Zioni, R" uniqKey="Zioni R">R. Zioni</name></author><author><name sortKey="Gifford, R J" uniqKey="Gifford R">R.J. Gifford</name></author><author><name sortKey="Holmes, S P" uniqKey="Holmes S">S.P. Holmes</name></author><author><name sortKey="Shafer, R W" uniqKey="Shafer R">R.W. Shafer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rizk, R Z" uniqKey="Rizk R">R.Z. Rizk</name></author><author><name sortKey="Christensen, N D" uniqKey="Christensen N">N.D. Christensen</name></author><author><name sortKey="Michael, K M" uniqKey="Michael K">K.M. Michael</name></author><author><name sortKey="Muller, M" uniqKey="Muller M">M. Muller</name></author><author><name sortKey="Sehr, P" uniqKey="Sehr P">P. Sehr</name></author><author><name sortKey="Waterboer, T" uniqKey="Waterboer T">T. Waterboer</name></author><author><name sortKey="Pawlita, M" uniqKey="Pawlita M">M. Pawlita</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Roden, R B" uniqKey="Roden R">R.B. Roden</name></author><author><name sortKey="Armstrong, A" uniqKey="Armstrong A">A. Armstrong</name></author><author><name sortKey="Haderer, P" uniqKey="Haderer P">P. Haderer</name></author><author><name sortKey="Christensen, N D" uniqKey="Christensen N">N.D. Christensen</name></author><author><name sortKey="Hubbert, N L" uniqKey="Hubbert N">N.L. Hubbert</name></author><author><name sortKey="Lowy, D R" uniqKey="Lowy D">D.R. Lowy</name></author><author><name sortKey="Schiller, J T" uniqKey="Schiller J">J.T. Schiller</name></author><author><name sortKey="Kirnbauer, R" uniqKey="Kirnbauer R">R. Kirnbauer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Romanowski, B" uniqKey="Romanowski B">B. Romanowski</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Roth, S D" uniqKey="Roth S">S.D. Roth</name></author><author><name sortKey="Sapp, M" uniqKey="Sapp M">M. Sapp</name></author><author><name sortKey="Streeck, R E" uniqKey="Streeck R">R.E. Streeck</name></author><author><name sortKey="Selinka, H C" uniqKey="Selinka H">H.C. Selinka</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schiller, J T" uniqKey="Schiller J">J.T. Schiller</name></author><author><name sortKey="Castellsague, X" uniqKey="Castellsague X">X. Castellsague</name></author><author><name sortKey="Garland, S M" uniqKey="Garland S">S.M. Garland</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schiller, J T" uniqKey="Schiller J">J.T. Schiller</name></author><author><name sortKey="Lowy, D R" uniqKey="Lowy D">D.R. Lowy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smith, J F" uniqKey="Smith J">J.F. Smith</name></author><author><name sortKey="Brownlow, M" uniqKey="Brownlow M">M. Brownlow</name></author><author><name sortKey="Brown, M" uniqKey="Brown M">M. Brown</name></author><author><name sortKey="Kowalski, R" uniqKey="Kowalski R">R. Kowalski</name></author><author><name sortKey="Esser, M T" uniqKey="Esser M">M.T. Esser</name></author><author><name sortKey="Ruiz, W" uniqKey="Ruiz W">W. Ruiz</name></author><author><name sortKey="Barr, E" uniqKey="Barr E">E. Barr</name></author><author><name sortKey="Brown, D R" uniqKey="Brown D">D.R. Brown</name></author><author><name sortKey="Bryan, J T" uniqKey="Bryan J">J.T. Bryan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smith, J F" uniqKey="Smith J">J.F. Smith</name></author><author><name sortKey="Kowalski, R" uniqKey="Kowalski R">R. Kowalski</name></author><author><name sortKey="Esser, M T" uniqKey="Esser M">M.T. Esser</name></author><author><name sortKey="Brown, M J" uniqKey="Brown M">M.J. Brown</name></author><author><name sortKey="Bryan, J T" uniqKey="Bryan J">J.T. Bryan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tamura, K" uniqKey="Tamura K">K. Tamura</name></author><author><name sortKey="Dudley, J" uniqKey="Dudley J">J. Dudley</name></author><author><name sortKey="Nei, M" uniqKey="Nei M">M. Nei</name></author><author><name sortKey="Kumar, S" uniqKey="Kumar S">S. Kumar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Touze, A" uniqKey="Touze A">A. Touze</name></author><author><name sortKey="El Mehdaoui, S" uniqKey="El Mehdaoui S">S. El Mehdaoui</name></author><author><name sortKey="Sizaret, P Y" uniqKey="Sizaret P">P.Y. Sizaret</name></author><author><name sortKey="Mougin, C" uniqKey="Mougin C">C. Mougin</name></author><author><name sortKey="Munoz, N" uniqKey="Munoz N">N. Munoz</name></author><author><name sortKey="Coursaget, P" uniqKey="Coursaget P">P. Coursaget</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van De Velde, N" uniqKey="Van De Velde N">N. Van de Velde</name></author><author><name sortKey="Boily, M C" uniqKey="Boily M">M.C. Boily</name></author><author><name sortKey="Drolet, M" uniqKey="Drolet M">M. Drolet</name></author><author><name sortKey="Franco, E L" uniqKey="Franco E">E.L. Franco</name></author><author><name sortKey="Mayrand, M H" uniqKey="Mayrand M">M.H. Mayrand</name></author><author><name sortKey="Kliewer, E V" uniqKey="Kliewer E">E.V. Kliewer</name></author><author><name sortKey="Coutlee, F" uniqKey="Coutlee F">F. Coutlee</name></author><author><name sortKey="Laprise, J F" uniqKey="Laprise J">J.F. Laprise</name></author><author><name sortKey="Malagon, T" uniqKey="Malagon T">T. Malagon</name></author><author><name sortKey="Brisson, M" uniqKey="Brisson M">M. Brisson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Varsani, A" uniqKey="Varsani A">A. Varsani</name></author><author><name sortKey="Williamson, A L" uniqKey="Williamson A">A.L. Williamson</name></author><author><name sortKey="Jaffer, M A" uniqKey="Jaffer M">M.A. Jaffer</name></author><author><name sortKey="Rybicki, E P" uniqKey="Rybicki E">E.P. Rybicki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, X" uniqKey="Wang X">X. Wang</name></author><author><name sortKey="Wang, Z" uniqKey="Wang Z">Z. Wang</name></author><author><name sortKey="Christensen, N D" uniqKey="Christensen N">N.D. Christensen</name></author><author><name sortKey="Dillner, J" uniqKey="Dillner J">J. Dillner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, Z" uniqKey="Wang Z">Z. Wang</name></author><author><name sortKey="Christensen, N" uniqKey="Christensen N">N. Christensen</name></author><author><name sortKey="Schiller, J T" uniqKey="Schiller J">J.T. Schiller</name></author><author><name sortKey="Dillner, J" uniqKey="Dillner J">J. Dillner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Woo, J" uniqKey="Woo J">J. Woo</name></author><author><name sortKey="Robertson, D L" uniqKey="Robertson D">D.L. Robertson</name></author><author><name sortKey="Lovell, S C" uniqKey="Lovell S">S.C. Lovell</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Genet Evol</journal-id><journal-id journal-id-type="iso-abbrev">Infect. Genet. Evol</journal-id><journal-title-group><journal-title>Infection, Genetics and Evolution</journal-title></journal-title-group><issn pub-type="ppub">1567-1348</issn><issn pub-type="epub">1567-7257</issn><publisher><publisher-name>Elsevier Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23722024</article-id><article-id pub-id-type="pmc">3769806</article-id><article-id pub-id-type="publisher-id">S1567-1348(13)00202-5</article-id><article-id pub-id-type="doi">10.1016/j.meegid.2013.05.013</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Amino acid sequence diversity of the major human papillomavirus capsid protein: Implications for current and next generation vaccines<sup><xref ref-type="fn" rid="d32e1209">☆</xref></sup></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ahmed</surname><given-names>Amina I.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bissett</surname><given-names>Sara L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Beddows</surname><given-names>Simon</given-names></name><email>simon.beddows@phe.gov.uk</email><xref rid="cor1" ref-type="corresp">⁎</xref></contrib></contrib-group><aff id="af005">Virus Reference Department, Public Health England, London, UK</aff><author-notes><corresp id="cor1"><label>⁎</label>Corresponding author. Address: Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK. Tel.: +44 (0) 20 8327 6169. <email>simon.beddows@phe.gov.uk</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>1</day><month>8</month><year>2013</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub"><month>8</month><year>2013</year></pub-date><volume>18</volume><fpage>151</fpage><lpage>159</lpage><history><date date-type="received"><day>11</day><month>4</month><year>2013</year></date><date date-type="rev-recd"><day>15</day><month>5</month><year>2013</year></date><date date-type="accepted"><day>17</day><month>5</month><year>2013</year></date></history><permissions><copyright-statement>© 2013 The Authors</copyright-statement><copyright-year>2013</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>Open Access under <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/3.0/">CC BY 3.0</ext-link> license</license-p></license></permissions><abstract abstract-type="author-highlights"><title>Highlights</title><p><list list-type="simple"><list-item id="o0005"><label>•</label><p>We evaluated amino acid diversity of the major capsid protein of HPV.</p></list-item><list-item id="o0010"><label>•</label><p>Residues displaying high entropy were found within surface-exposed domains.</p></list-item><list-item id="o0015"><label>•</label><p>We discuss the implications of this diversity on the current and next generation HPV vaccines.</p></list-item></list></p></abstract><abstract><p>Despite the fidelity of host cell polymerases, the human papillomavirus (HPV) displays a degree of genomic polymorphism resulting in distinct genotypes and intra-type variants. The current HPV vaccines target the most prevalent genotypes associated with cervical cancer (HPV16/18) and genital warts (HPV6/11). Although these vaccines confer some measure of cross-protection, a multivalent HPV vaccine is in the pipeline that aims to broaden vaccine protection against other cervical cancer-associated genotypes including HPV31, HPV33, HPV45, HPV52 and HPV58. Both current and next generation vaccines comprise virus-like particles, based upon the major capsid protein, L1, and vaccine-induced, type-specific protection is likely mediated by neutralizing antibodies targeting L1 surface-exposed domains.</p><p>The aim of this study was to perform an <italic>in silico</italic> analysis of existing full length L1 sequences representing vaccine-relevant HPV genotypes in order to address the degree of naturally-occurring, intra-type polymorphisms. In total, 1281 sequences from the Americas, Africa, Asia and Europe were assembled. Intra-type entropy was low and/or limited to non-surface-exposed residues for HPV6, HPV11 and HPV52 suggesting a minimal effect on vaccine antibodies for these genotypes. For HPV16, intra-type entropy was high but the present analysis did not reveal any significant polymorphisms not previously identified. For HPV31, HPV33, HPV58, however, intra-type entropy was high, mostly mapped to surface-exposed domains and in some cases within known neutralizing antibody epitopes. For HPV18 and HPV45 there were too few sequences for a definitive analysis, but HPV45 displayed some degree of surface-exposed residue diversity. In most cases, the reference sequence for each genotype represented a minority variant and the consensus L1 sequences for HPV18, HPV31, HPV45 and HPV58 did not reflect the L1 sequence of the currently available HPV pseudoviruses. These data highlight a number of variant amino acid residues that warrant further investigation for vaccine and natural history studies of HPV.</p></abstract><kwd-group><title>Keywords</title><kwd>Papillomavirus</kwd><kwd>HPV</kwd><kwd>Diversity</kwd><kwd>Entropy</kwd><kwd>L1</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s0005"><label>1</label><title>Introduction</title><p>Cervical cancer is the third most common cancer of women, accounting for an estimated 530,000 cases and 275,000 deaths per annum worldwide (<xref rid="b0005" ref-type="bibr">Arbyn et al., 2011</xref>). Although there are some geographical differences, human papillomavirus (HPV) genotypes HPV16 and HPV18 are associated with approximately 70% of cervical cancer cases (<xref rid="b0145" ref-type="bibr">Li et al., 2010</xref>). Virus-like particle (VLP) vaccines (Cervarix® and Gardasil®) based on the major capsid (L1) proteins of HPV16 and HPV18 have demonstrated almost 100% efficacy against high grade lesions associated with these two types in clinical trials (<xref rid="b0160 b0220" ref-type="bibr">Lu et al., 2011; Romanowski, 2011</xref>). Gardasil® also contains VLP representing HPV6 and HPV11 which are associated with the development of genital warts.</p><p>Serological assays for the evaluation of vaccine antibody responses and natural history studies of HPV infection include competitive and direct immunoassays (<xref rid="b0085 b0110" ref-type="bibr">Dias et al., 2005; Giannini et al., 2006</xref>) and a pseudovirus-based neutralization assay (<xref rid="b0195" ref-type="bibr">Pastrana et al., 2004</xref>). All these systems have potential shortcomings that affect their utility in monitoring vaccine-induced antibody responses (<xref rid="b0230" ref-type="bibr">Schiller et al., 2012</xref>). However, the detection of high titer, type-specific neutralizing antibodies in the serum and cervico-vaginal secretions of human vaccines (<xref rid="b0095" ref-type="bibr">Einstein et al., 2009</xref>) and antibody-mediated protection in animal models (<xref rid="b0155" ref-type="bibr">Longet et al., 2011</xref>) has led to the reasonable assumption that antibodies are the principal mediators of type-specific vaccine-induced protection (<xref rid="b0235" ref-type="bibr">Schiller and Lowy, 2012</xref>). Type-specific seroconversion following natural infection is less efficient (<xref rid="b0040" ref-type="bibr">Carter et al., 2000</xref>) but appears to be associated with some degree of protection against subsequent infection (<xref rid="b0150" ref-type="bibr">Lin et al., 2013</xref>).</p><p>Closely-related HPV types within the alpha-papillomavirus species groups A9 (HPV16-like: HPV31, HPV33, HPV35, HPV52 and HPV58) and A7 (HPV18 like: HPV39, HPV45, HPV59 and HPV68) are associated with a further <italic>ca</italic>. 25% of cervical cancers worldwide, although there are geographical differences in the relative distribution of these types (<xref rid="b0145" ref-type="bibr">Li et al., 2010</xref>). The current generation of HPV vaccines afford some degree of cross-protection against a few of these types including HPV31, HPV33 and HPV45 but probably not HPV52 and HPV58 (<xref rid="b0160 b0220" ref-type="bibr">Lu et al., 2011; Romanowski, 2011</xref>). This protection is at least coincident with the detection of neutralizing antibodies in the serum of vaccinated individuals (<xref rid="b0090 b0100 b0130" ref-type="bibr">Draper et al., 2011; Einstein et al., 2011; Kemp et al., 2011</xref>). The limited degree of cross-protection afforded by the current generation of VLP-based vaccines has led to the development of a candidate next generation multivalent VLP-based vaccine to extend coverage to a wider array of HPV types (<xref rid="b0260" ref-type="bibr">Van de Velde et al., 2012</xref>).</p><p>Despite the excellent proof-reading ability of host cell polymerases, the approximately 8 kb double-stranded DNA genome of HPV displays a certain degree of intra-type genome polymorphism (<xref rid="b0060 b0065" ref-type="bibr">Chen et al., 2009, 2011</xref>). Such variants are predicted to have arisen over millennia due to the slow evolutionary rate of the genome (estimated to be 10<sup>−8</sup> base substitutions per site per year) (<xref rid="b0060" ref-type="bibr">Chen et al., 2009</xref>). The extent of HPV genome diversity, the interplay between positive and negative selection pressures and genetic drift, and the biological consequences of such variation are largely unclear (<xref rid="b0010" ref-type="bibr">Bernard et al., 2006</xref>).</p><p>Serological cross-reactivity in ELISA (<xref rid="b0070 b0255" ref-type="bibr">Cheng et al., 1995; Touze et al., 1998</xref>) and neutralization (<xref rid="b0200" ref-type="bibr">Pastrana et al., 2001</xref>) assays using targets representing HPV16 variants suggested that the most common HPV16 L1 polymorphisms are unlikely to adversely influence the effectiveness of an HPV vaccine based upon a single HPV16 L1 sequence. This hypothesis appears to have been confirmed by HPV16/18 vaccine efficacy data reported from clinical trials carried out in the Americas, Europe and the Asia–Pacific region (<xref rid="b0175 b0190" ref-type="bibr">Munoz et al., 2010; Paavonen et al., 2007</xref>).</p><p>VLP assembly follows a step-wise process in which five L1 monomers form an intermediate structure (known as a capsomer) and then these pentameric subunits associate to form an icosahedral structure of 72 capsomers (<xref rid="b0055" ref-type="bibr">Chen et al., 2000</xref>). The highest degree of inter-type diversity is located within the external loops of the L1 protein and is thought to contribute to the differences in antigenicity between papillomavirus types (<xref rid="b0015 b0055" ref-type="bibr">Bishop et al., 2007; Chen et al., 2000</xref>). Until recently, most studies examining intra-type variation of the major capsid protein have focussed on small fragments of the L1 gene. More recently, a number of studies have published full length L1 or full genome HPV sequences and consequently a detailed structural picture of intra-type variation is now possible. This study sought to perform an evaluation of worldwide L1 amino acid diversity for a range of vaccine-relevant HPV types, using available full length L1 sequences, and postulate upon the impact that such polymorphisms would have on current and candidate L1-based vaccines.</p></sec><sec sec-type="materials|methods" id="s0010"><label>2</label><title>Materials and methods</title><sec id="s0015"><label>2.1</label><title>Source of available sequences</title><p>Reference sequence accession numbers and the taxonomy identifiers for each HPV type are as indicated: HPV6 (X00203; txid31552; [6a] txid37122; [6b] txid10600), HPV11 (M14119; txid10580), HPV16 (HPV16R: corrected version of K02718 (<xref rid="b0180" ref-type="bibr">Myers et al., 1995</xref>); txid333760), HPV18 (HPV18R: AY262282, corrected version of X05015; txid333761), HPV31 (J04353; txid10585), HPV33 (M12732; txid10586), HPV45 (X74479; txid10593), HPV52 (X74481; txid10618) and HPV58 (D90400; txid10598) (<xref rid="b0075" ref-type="bibr">de Villiers et al., 2004</xref>). The reference sequences are the same as those given in the Papillomavirus Episteme database (<ext-link ext-link-type="uri" xlink:href="http://pave.niaid.nih.gov" id="ir0005">http://pave.niaid.nih.gov</ext-link>). Sequences were downloaded from the National Center for Biotechnology Information (NCBI; <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/" id="ir0020">http://www.ncbi.nlm.nih.gov/</ext-link>) between November and December 2012. A referenced source list of the sequences used in this study can be found in <xref rid="s0065" ref-type="sec">Supplementary Table S1</xref>. Only full length L1 sequences were considered for this analysis. For some studies, only one sequence was deposited in the NCBI database to represent multiple occurrences of a variant; in these cases, the prevalence of individual variant sequences was calculated using the numbers indicated in the relevant publication. The consensus sequence was generated from the panel of assembled sequences for each genotype by selecting the most frequent amino acid present at a given position, which may or may not be the same as the reference sequence.</p></sec><sec id="s0020"><label>2.2</label><title>Site-specific residue variation and mapping</title><p>Sequences were aligned, translated and exported as a FASTA formatted file using MEGA v4.1 (<xref rid="b0250" ref-type="bibr">Tamura et al., 2007</xref>). Residue positions were numbered according to the initiating ATG codon of the L1 protein coding sequence (CDS; <ext-link ext-link-type="uri" xlink:href="http://pave.niaid.nih.gov" id="ir0010">http://pave.niaid.nih.gov</ext-link>) of the appropriate reference sequence, according to convention (<xref rid="b0015 b0055" ref-type="bibr">Bishop et al., 2007; Chen et al., 2000</xref>). For example, and for the purposes of clarity, the HPV16 L1 protein starts with the MSLW motif. Amino acid substitutions are designated X123Y, where X is the amino acid at reference sequence residue position 123 that is substituted by amino acid Y in the variant. Deletions are indicated by a Δ. Site-specific Shannon entropy was determined using the aligned amino acid sequences for each type using the <italic>Entropy One</italic> program on the Los Alamos National Laboratory website (<ext-link ext-link-type="uri" xlink:href="http://www.hiv.lanl.gov/content/sequence/ENTROPY/entropy_one.html" id="ir0025">http://www.hiv.lanl.gov/content/sequence/ENTROPY/entropy_one.html</ext-link>) (<xref rid="b0140" ref-type="bibr">Korber et al., 1994</xref>). For comparison purposes, a level of 5% residue variation equates to an entropy score of <italic>ca</italic>. 0.18. Protein secondary structures (amino [Nt] and carboxy [Ct] termini, α-helices, β-sheets and external loops [BC, DE, EF, FG, HI]) were highlighted accordingly (<xref rid="b0015" ref-type="bibr">Bishop et al., 2007</xref>). Variant residues were mapped to the surface of the HPV16 capsomer crystal structure (PDB code: 2R5H) using Swiss-PDP viewer v4.0 (Deep View) (<xref rid="b0115" ref-type="bibr">Guex and Peitsch, 1997</xref>).</p></sec><sec id="s0025"><label>2.3</label><title>Statistical analysis</title><p>Differences in entropy between loop and non-loop residues (non parametric, Mann–Whitney <italic>U</italic> test) and differences in proportions in geographic distribution (2-tailed Fisher’s exact test) were evaluated using Stata 12.0 (StataCorp, Tx., USA).</p></sec></sec><sec id="s0030"><label>3</label><title>Results and discussion</title><sec id="s0035"><label>3.1</label><title>HPV6/11</title><p>HPV6 and HPV11 genotypes were represented by <italic>n</italic> = 136 and <italic>n</italic> = 103 sequences, respectively, with the majority (94%) being from Europe (<xref rid="f0005" ref-type="fig">Fig. 1</xref>). There were no full length sequences from Africa and few from the Americas (2%) or Asia (4%). The reference sequences for HPV6 and HPV11 were the same as their respective consensus sequence and represented 76% (95% CI, 68–83%) and 86% (95% CI, 78–92%) of HPV6 and HPV11 full length L1 sequences, respectively. In both cases, the pseudovirus L1 sequence was the same as the consensus and the reference sequence.</p><p>HPV6 L1 sequence variation was low (<xref rid="f0010" ref-type="fig">Fig. 2</xref>) with 17% of sequences incorporating an E431Q substitution in the α4-βJ region (<xref rid="t0005" ref-type="table">Table 1</xref>). The E431Q substitution does not appear to have an impact on VLP stability (<xref rid="b0030" ref-type="bibr">Caparros-Wanderley et al., 1999</xref>). HPV6 vaccine antibodies are evaluated by competition with the type-specific neutralizing monoclonal antibody (MAb) H6.M48 (<xref rid="b0085 b0245" ref-type="bibr">Dias et al., 2005; Smith et al., 2008</xref>). The epitope of this MAb appears to localize to the BC loop, with possible contribution from the EF loop, while antibodies generated during natural infection appear to bind to a range of epitopes (<xref rid="b0170 b0185" ref-type="bibr">McClements et al., 2001; Orozco et al., 2005</xref>).</p><p>HPV11 L1 sequence variation was low (<xref rid="f0010" ref-type="fig">Fig. 2</xref>) with 7% of sequences incorporating an A235S substitution in the α1 region (<xref rid="t0005" ref-type="table">Table 1</xref>). HPV11 vaccine antibodies are monitored through competition with the type-specific neutralizing MAb K11.B2 (<xref rid="b0085 b0245" ref-type="bibr">Dias et al., 2005; Smith et al., 2008</xref>). The epitope of this MAb is unclear. MAb K11.B2 replaced MAb H11.B2 during development of the competitive assay and the epitope of this latter MAb was identified within the DE loop (<xref rid="b0165 b0185" ref-type="bibr">Ludmerer et al., 1996; Orozco et al., 2005</xref>). Antibodies generated following natural infection appear to target epitopes in the C-terminal (Ct) portion downstream of the DE loop (<xref rid="b0270" ref-type="bibr">Wang et al., 2003</xref>).</p><p>There were too few non-European sequences available to evaluate the geographical distribution of the HPV6 E431Q and HPV11 A235S variants.</p></sec><sec id="s0040"><label>3.2</label><title>HPV16, HPV31, HPV33, HPV52 and HPV58</title><p>HPV16 (<italic>n</italic> = 183), HPV52 (<italic>n</italic> = 205) and HPV58 (<italic>n</italic> = 465) were well represented within the dataset, with HPV31 (<italic>n</italic> = 95) and HPV33 (<italic>n</italic> = 58) less so. Each genotype was represented by sequences from Africa, the Americas and Asia, albeit to varying degrees, but European sequences were only available for HPV16 and HPV58, at 3% and 7% of the total, respectively (<xref rid="f0005" ref-type="fig">Fig. 1</xref>). The available number of sequences and the degree of intra-type variation was sufficient to enable mapping the entropy score of surface exposed residues for each A9 genotype onto the crystal structure of the HPV16 capsomer (<xref rid="f0015" ref-type="fig">Fig. 3</xref>).</p><p>The reference sequence for HPV16 represented only 7% (95% CI, 3–11%) of sequences. The consensus sequence differed from the reference by a T266A substitution in the FG loop, represented 37% (95% CI, 30–44%) of sequences overall and could be found in all four geographical regions. The HPV16 pseudovirus L1 sequence was identical to the consensus. In addition to the T266A polymorphism, several variable sites within structural domains (H76Y, T389S, L475F) or within the EF (T176N, N181T), FG (S282P) and HI (T353P) loops were found in these sequences (<xref rid="f0010" ref-type="fig">Fig. 2</xref>), in a variety of combinations (<xref rid="s0065" ref-type="sec">Supplementary Fig. S1</xref>). Surface-exposed residues that exhibited the highest degree of variation did not appear to form a distinct cluster but instead could be found dispersed along the ridge of the EF loop and its base (adjacent to the FG/HI loops) (<xref rid="f0015" ref-type="fig">Fig. 3</xref>A, 3B HPV16). The H76Y, T176N, S282P and L475F mutations were overrepresented in sequences from Africa, while the H76Y and L475F mutations were underrepresented in sequences from Asia relative to the overall mean (<xref rid="t0005" ref-type="table">Table 1</xref>). The HPV16 VLP in the Cervarix® vaccine matches the consensus sequence, including the T266A substitution (<xref rid="b0080" ref-type="bibr">Deschuyteneer et al., 2010</xref>). HPV16 vaccine antibodies are monitored by competition with the type-specific neutralizing MAb H16.V5 (<xref rid="b0085 b0110 b0245" ref-type="bibr">Dias et al., 2005; Giannini et al., 2006; Smith et al., 2008</xref>). This MAb targets a conformational epitope in the FG loop, with possible contribution from the HI loop (<xref rid="b0045" ref-type="bibr">Carter et al., 2003</xref>) and is thought to represent a significant proportion, but not the entirety, of antibody specificities produced during natural infection (<xref rid="b0045 b0275" ref-type="bibr">Carter et al., 2003; Wang et al., 1997</xref>). Using a series of HPV16:HPV31 loop-swap hybrid VLP, HPV16-specific antibodies generated during natural infection appeared to target the DE, FG, and HI loops (<xref rid="b0050" ref-type="bibr">Carter et al., 2006</xref>). The H76Y, T176N, N181T, S282P, T353P, T389S and L475F mutations have been substituted into an HPV16 pseudovirus L1 backbone based upon the European variant 114/K (Accession no. EU118173, identical to the consensus reported here) and found not to have a significant impact on recognition by antibodies elicited to HPV16 (<xref rid="b0200" ref-type="bibr">Pastrana et al., 2001</xref>). The binding and neutralization of MAb H16.E70, however, appears to be affected by substitutions in the FG loop, including the reciprocal A266T mutation which was present in <italic>ca</italic>. 11% of sequences (<xref rid="b0045 b0215 b0265" ref-type="bibr">Carter et al., 2003; Roden et al., 1997; Varsani et al., 2006</xref>).</p><p>The reference sequence for HPV31 represented only 12% (95% CI, 6–20%) of sequences and was the same as the pseudovirus sequence. The HPV31 L1 protein exhibited variation in the α4-βJ region (T432S in 7% of sequences) and the FG loop (T267A and T274N; in 49% and 78% of sequences, respectively) (<xref rid="f0010" ref-type="fig">Fig. 2</xref> and <xref rid="t0005" ref-type="table">Table 1</xref>), in a limited number of combinations (<xref rid="s0065" ref-type="sec">Supplementary Fig. S1</xref>). The T267A and T274N residues are located at distinct sites on the surface of the FG loop (<xref rid="f0015" ref-type="fig">Fig. 3</xref>A, 3B HPV31). There were too few African and Asian sequences to ascertain the proportions of their distribution outside of the Americas. HPV31 MAbs have been shown to target both the EF and FG loops. MAb H31.A6 bound VLP containing the HPV31 EF loop in a HPV16 backbone, but not the reciprocal mutant (<xref rid="b0045" ref-type="bibr">Carter et al., 2003</xref>). Three HPV31 MAbs have been identified as targeting the FG loop, including an epitope encompassing the T267A variant residue (<xref rid="b0105" ref-type="bibr">Fleury et al., 2009</xref>), while another study demonstrated that cross-reactive HPV16/HPV31 MAbs share a common binding motif in the FG loop (<xref rid="b0035" ref-type="bibr">Carpentier et al., 2005</xref>). The FG loop variants T267A and T274N may, therefore, have an impact on the epitope configuration of some HPV31-specific antibodies.</p><p>The reference sequence for HPV33 represented 48% (95% CI, 35–62%) of sequences examined and was identical to both the consensus and pseudovirus sequences. There were six sites of significant variation in the HPV33 L1 protein, including variation in the BC (T56N), DE (G133S, K135R), FG (T266K/N, G268E) loops and the Ct (K495R) (<xref rid="f0010" ref-type="fig">Fig. 2</xref>, <xref rid="t0005" ref-type="table">Table 1</xref>). Despite the number of individual variant residues, the number of variant sequences containing multiple variant sites was fairly limited (<xref rid="s0065" ref-type="sec">Supplementary Fig. S1</xref>). The major variant residues of HPV33 were dispersed across the surface of the capsomer (<xref rid="f0015" ref-type="fig">Fig. 3</xref>A and B HPV33), including the tip of the BC loop, a small cleft at the base of the BC and EF loops (adjacent to the FG loop) and the capsomer lumen. The most common variant positions (T56N, G133S, T266K, K495R) were found in the Americas, Asia and Africa, although the latter two regions were represented by too few sequences (<italic>n</italic> = 5 and 7, respectively) to evaluate their proportionate distribution. Three HPV33 MAbs (H33.J3, H33.B6 and H33.E12) have been identified as binding conformational epitopes within the BC, DE and FG loops (<xref rid="b0225" ref-type="bibr">Roth et al., 2006</xref>). H33.J3 appears to target a discrete epitope within the BC loop of HPV33 and was able to neutralize an HPV16:HPV31BC hybrid and wild-type HPV33 but not wild-type HPV16 (<xref rid="b0225" ref-type="bibr">Roth et al., 2006</xref>). Naturally occurring residue variations within the BC, DE and FG loops, as highlighted in this study, may therefore affect recognition by these MAbs and, by implication, neutralizing antibodies generated to the HPV33 L1 protein.</p><p>The reference, consensus and pseudovirus sequences for HPV52 were identical, representing 81% (95% CI, 75–87%) of sequences and could be found in the Americas, Asia and Africa. There were four main sites of variation in the HPV52 L1 protein (<xref rid="f0010" ref-type="fig">Fig. 2</xref>), located in the FG (Q282K) and HI (K355T, S358D/N) loops and the α4-βJ region (D448E) found on a limited number of variant sequences (<xref rid="s0065" ref-type="sec">Supplementary Fig. S1</xref>). Three of these (Q282K, K355T, S358D/N) appeared to form a distinct cluster along the edges of the FG/HI loops (<xref rid="f0015" ref-type="fig">Fig. 3</xref>A, 3B HPV52). Overall, these variants were present in <10% of sequences (<xref rid="t0005" ref-type="table">Table 1</xref>) and tended to be underrepresented in sequences from Asia. There were few data available on the specificity of HPV52 MAbs (<xref rid="b0210" ref-type="bibr">Rizk et al., 2008</xref>). HPV52 VLP incorporating the BC loop of HPV16 reduced, but did not eliminate, the binding of four HPV52 MAbs, suggesting that this region may contribute to the formation of an immunodominant domain (<xref rid="b0045" ref-type="bibr">Carter et al., 2003</xref>). The implications of variation within the FG and HI loops, as outlined herein, are uncertain. The Q282K substitution restores a Lysine residue that, for HPV16 (K278) at least, is thought to be important for cell binding via heparin moieties (<xref rid="b0135" ref-type="bibr">Knappe et al., 2007</xref>). No other HPV types exhibited significant (⩾5%) variation within these putative heparin-binding sites.</p><p>The reference sequence for HPV58 represented only 6% (95% CI, 4–9%) of sequences. The consensus sequence differed from the reference by L124F (DE loop) and I299M/L (βG1 region) substitutions, represented 62% (95% CI, 58–67%) of sequences examined and could be found in all four geographical regions. The pseudovirus sequence for HPV58 was the same as the reference and therefore did not represent the consensus of circulating sequences. Variation across the L1 protein was greater for HPV58 than any of the types evaluated (<xref rid="f0010" ref-type="fig">Fig. 2</xref>) and predominantly associated with the external loops (<italic>p </italic>< 0.001). Variant residues were found in internal domains including βG1 (I299M/L), α2 (I386V), α2-α3 (D394N), α3 (N396D) and the DE (V118I, L124F, S133G, P137T), FG (K266T/N, A270P, D273 N, V285G/A) and HI (T349 N, G352D, D357N) loops. These variant residues could be found in various combinations within 21 distinct variant sequences (<xref rid="s0065" ref-type="sec">Supplementary Fig. S1</xref>). Most of the surface-exposed variant residues formed part of distinct clusters of sites between the bases of the BC and EF loops and the distal portion of the FG and HI loops (<xref rid="f0015" ref-type="fig">Fig. 3</xref>A and B HPV58). The pentamer lumen also exhibited a degree of variation. With the exceptions of the L124F, I299M/L and T349N mutations the remainder were highly overrepresented in African and underrepresented in Asian sequences (<xref rid="t0005" ref-type="table">Table 1</xref>). A limited number of HPV58 MAbs have been generated and these appear to exhibit a range of target specificities (<xref rid="b0020" ref-type="bibr">Brendle et al., 2010</xref>) although detailed epitopes have not been defined.</p></sec><sec id="s0045"><label>3.3</label><title>HPV18 and HPV45</title><p>There were few HPV18 (<italic>n</italic> = 23) and HPV45 (<italic>n</italic> = 13) full length L1 sequences available for analysis. The majority of the HPV18 and all of the HPV45 sequences were from the Americas, with no available sequences from Europe or Africa (<xref rid="f0005" ref-type="fig">Fig. 1</xref>), prohibiting an evaluation of geographic distribution of individual variants.</p><p>The reference sequence for HPV18 represented 39% (95% CI, 20–61%) of sequences. The consensus sequence for HPV18 differed from the reference by a T88N substitution (present in 57% of sequences) in the βC-βD region, although the consensus sequence itself was only represented by a single sequence. The pseudovirus sequence for HPV18 was the same as the reference and therefore did not represent the consensus sequence. The majority of substitutions were located within internal structural domains (L3M, A103V, V323I) (<xref rid="f0010" ref-type="fig">Fig. 2</xref>), with the exception of one substitution, Q273P, found within the FG loop (<xref rid="t0005" ref-type="table">Table 1</xref>). These variant residues were found in a limited number of combinations (<xref rid="s0065" ref-type="sec">Supplementary Fig. S1</xref>). HPV18 VLP used in the Cervarix® vaccine appear to contain the T88N, A103V and Q273P but not the L3M and V323I substitutions (<xref rid="b0080" ref-type="bibr">Deschuyteneer et al., 2010</xref>). HPV18 vaccine antibodies are monitored by competition with MAb H18.J4 (<xref rid="b0085 b0110 b0245" ref-type="bibr">Dias et al., 2005; Giannini et al., 2006; Smith et al., 2008</xref>) which recognizes a predominantly type-specific conformational neutralizing epitope (<xref rid="b0240" ref-type="bibr">Smith et al., 2007</xref>).</p><p>The reference sequence for HPV45 represented only 1/13 sequences (8%; 95% CI, 2–36%). There were a number of variant residues relative to the reference sequence (<xref rid="f0010" ref-type="fig">Fig. 2</xref>) including those in the structural domains Nt-βB1 (S23N), βG1 (I303T), HI-β1 (Q366H), Ct (Δ499–501) and the BC (N55S), DE (I140V), FG (E287D) and HI (N353T, S357G/N) loops but too few sequences overall to evaluate the proportions of these variants appropriately (<xref rid="t0005" ref-type="table">Table 1</xref>). These variant residues were found in a limited number of combinations (<xref rid="s0065" ref-type="sec">Supplementary Fig. S1</xref>). The pseudovirus sequence for HPV45 was the same as the reference. MAbs raised against HPV45 VLP are directed towards conformational epitopes and can be either type-specific or cross-reactive (<xref rid="b0240" ref-type="bibr">Smith et al., 2007</xref>), though the exact epitope(s) are not available.</p></sec></sec><sec sec-type="conclusions" id="s0050"><label>4</label><title>Conclusions</title><p>The number of available full length L1 sequences for some of the HPV types limited the precision of estimates around the proportions of site-specific variation. Most A10 species group sequences were from Europe while the majority of the A7 and A9 species group sequences were from the Americas or Asia. There was a paucity of African sequences overall and of European sequences representing A7 and A9 species group genotypes. In addition, it is possible that the deposition of sequences has been skewed towards the reporting of more variant sequences rather than sequences that match the reference. Taken together, any empirical evaluation of site-specific residue variation will likely be somewhat biased by the disparate distribution of the available sequences, a common problem with this kind of assessment. Nevertheless, the number of sequences was sufficient to highlight the representativeness, or not, of the reference and pseudovirus sequences and significant sites of intra-type variation for further study.</p><p>The reference sequence was the same as the consensus sequence for HPV6, HPV11, HPV33 and HPV52 but for the other types represented a minority variant. The pseudovirus L1 sequence was representative of the consensus sequence for HPV6, HPV11, HPV16, HPV33 and HPV52. For the remainder (HPV18, HPV31, HPV45 and HPV58) the pseudovirus sequence was based upon the reference sequence and was therefore not representative of the majority of circulating HPV sequences. The lack of representation of the consensus sequences in the pseudoviruses may not be a significant issue provided naturally occurring deviations do not negatively impact the functional utility of the pseudovirus assay. For studies of natural infection, therefore, it may be appropriate to evaluate empirically the implications of these deviations from the pseudovirus sequence.</p><p>Inter-type entropy, generated using the consensus for each type, was high and localized to the external loops (<italic>p</italic> < 0.001; <xref rid="s0065" ref-type="sec">Supplementary Fig. S2</xref>) as expected (<xref rid="b0055" ref-type="bibr">Chen et al., 2000</xref>). A difference in the intra-type entropy scores between the external loops and internal structural regions was only found for HPV58, however, reflecting both the high volume of available L1 sequences and the degree of variation for this HPV type. Intra-type entropy was more sporadic and generally of lower magnitude than similar evaluations for RNA viruses such as HIV-1 (<xref rid="b0205 b0280" ref-type="bibr">Rhee et al., 2008; Woo et al., 2010</xref>), Influenza (<xref rid="b0120" ref-type="bibr">Huang et al., 2012</xref>) and Norovirus (<xref rid="b0125" ref-type="bibr">Jin et al., 2011</xref>) reflecting the excellent proof-reading capability of host cell polymerases and the apparent timescale in which these variants have arisen (<xref rid="b0060" ref-type="bibr">Chen et al., 2009</xref>).</p><p>Sites of variation for HPV6, HPV11, and to some extent for HPV52, were rare or confined to a limited number of internal residues suggesting that the impact of these polymorphisms on recognition by L1-specific antibodies is unlikely to be significant. For HPV16, the most common sites of variation (apart from the reciprocal A266T variant) have already been evaluated (<xref rid="b0200" ref-type="bibr">Pastrana et al., 2001</xref>) and demonstrate a limited effect on antibody recognition. For the remaining HPV types, the degree of site-specific variation was high and in some cases within domains implicated in the recognition by L1-specific antibodies. This was particularly evident for HPV31, HPV33 and HPV58. For HPV31 and HPV33 the residues exhibiting the highest degree of variation tended to be in discrete sites while for HPV58 these residues appeared to be localized into distinct clusters. Some HPV types exhibited a degree of variation within the lumen of the capsomer which has potential implications for the interaction with the minor capsid protein, L2 (<xref rid="b0025" ref-type="bibr">Buck et al., 2008</xref>).</p><p>The consequences of these polymorphisms for recognition by antibodies elicited following natural infection or vaccination by the current and next generation vaccines warrants further investigation.</p></sec><sec id="s0055"><title>Funding</title><p>This work received no specific grant from any funding agency in the public or commercial sectors.</p></sec></body><back><ref-list><title>References</title><ref id="b0005"><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name><surname>Arbyn</surname><given-names>M.</given-names></name><name><surname>Castellsague</surname><given-names>X.</given-names></name><name><surname>de Sanjose</surname><given-names>S.</given-names></name><name><surname>Bruni</surname><given-names>L.</given-names></name><name><surname>Saraiya</surname><given-names>M.</given-names></name><name><surname>Bray</surname><given-names>F.</given-names></name><name><surname>Ferlay</surname><given-names>J.</given-names></name></person-group><article-title>Worldwide burden of cervical cancer in 2008</article-title><source>Ann. Oncol.</source><volume>22</volume><year>2011</year><fpage>2675</fpage><lpage>2686</lpage><pub-id pub-id-type="pmid">21471563</pub-id></element-citation></ref><ref id="b0010"><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>H.U.</given-names></name><name><surname>Calleja-Macias</surname><given-names>I.E.</given-names></name><name><surname>Dunn</surname><given-names>S.T.</given-names></name></person-group><article-title>Genome variation of human papillomavirus types: phylogenetic and medical implications</article-title><source>Int. J. Cancer</source><volume>118</volume><year>2006</year><fpage>1071</fpage><lpage>1076</lpage><pub-id pub-id-type="pmid">16331617</pub-id></element-citation></ref><ref id="b0015"><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name><surname>Bishop</surname><given-names>B.</given-names></name><name><surname>Dasgupta</surname><given-names>J.</given-names></name><name><surname>Klein</surname><given-names>M.</given-names></name><name><surname>Garcea</surname><given-names>R.L.</given-names></name><name><surname>Christensen</surname><given-names>N.D.</given-names></name><name><surname>Zhao</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>X.S.</given-names></name></person-group><article-title>Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies</article-title><source>J. Biol. Chem.</source><volume>282</volume><year>2007</year><fpage>31803</fpage><lpage>31811</lpage><pub-id pub-id-type="pmid">17804402</pub-id></element-citation></ref><ref id="b0020"><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name><surname>Brendle</surname><given-names>S.A.</given-names></name><name><surname>Culp</surname><given-names>T.D.</given-names></name><name><surname>Broutian</surname><given-names>T.R.</given-names></name><name><surname>Christensen</surname><given-names>N.D.</given-names></name></person-group><article-title>Binding and neutralization characteristics of a panel of monoclonal antibodies to human papillomavirus 58</article-title><source>J. Gen. Virol.</source><volume>91</volume><year>2010</year><fpage>1834</fpage><lpage>1839</lpage><pub-id pub-id-type="pmid">20181746</pub-id></element-citation></ref><ref id="b0025"><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name><surname>Buck</surname><given-names>C.B.</given-names></name><name><surname>Cheng</surname><given-names>N.</given-names></name><name><surname>Thompson</surname><given-names>C.D.</given-names></name><name><surname>Lowy</surname><given-names>D.R.</given-names></name><name><surname>Steven</surname><given-names>A.C.</given-names></name><name><surname>Schiller</surname><given-names>J.T.</given-names></name><name><surname>Trus</surname><given-names>B.L.</given-names></name></person-group><article-title>Arrangement of L2 within the papillomavirus capsid</article-title><source>J. Virol.</source><volume>82</volume><year>2008</year><fpage>5190</fpage><lpage>5197</lpage><pub-id pub-id-type="pmid">18367526</pub-id></element-citation></ref><ref id="b0030"><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name><surname>Caparros-Wanderley</surname><given-names>W.</given-names></name><name><surname>Savage</surname><given-names>N.</given-names></name><name><surname>Hill-Perkins</surname><given-names>M.</given-names></name><name><surname>Layton</surname><given-names>G.</given-names></name><name><surname>Weber</surname><given-names>J.</given-names></name><name><surname>Davies</surname><given-names>D.H.</given-names></name></person-group><article-title>Intratype sequence variation among clinical isolates of the human papillomavirus type 6 L1 ORF: clustering of mutations and identification of a frequent amino acid sequence variant</article-title><source>J. Gen. Virol.</source><volume>80</volume><year>1999</year><fpage>1025</fpage><lpage>1033</lpage><pub-id pub-id-type="pmid">10211973</pub-id></element-citation></ref><ref id="b0035"><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name><surname>Carpentier</surname><given-names>G.S.</given-names></name><name><surname>Fleury</surname><given-names>M.J.</given-names></name><name><surname>Touze</surname><given-names>A.</given-names></name><name><surname>Sadeyen</surname><given-names>J.R.</given-names></name><name><surname>Tourne</surname><given-names>S.</given-names></name><name><surname>Sizaret</surname><given-names>P.Y.</given-names></name><name><surname>Coursaget</surname><given-names>P.</given-names></name></person-group><article-title>Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies</article-title><source>J. Med. Virol.</source><volume>77</volume><year>2005</year><fpage>558</fpage><lpage>565</lpage><pub-id pub-id-type="pmid">16254978</pub-id></element-citation></ref><ref id="b0040"><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>J.J.</given-names></name><name><surname>Koutsky</surname><given-names>L.A.</given-names></name><name><surname>Hughes</surname><given-names>J.P.</given-names></name><name><surname>Lee</surname><given-names>S.K.</given-names></name><name><surname>Kuypers</surname><given-names>J.</given-names></name><name><surname>Kiviat</surname><given-names>N.</given-names></name><name><surname>Galloway</surname><given-names>D.A.</given-names></name></person-group><article-title>Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection</article-title><source>J. Infect. Dis.</source><volume>181</volume><year>2000</year><fpage>1911</fpage><lpage>1919</lpage><pub-id pub-id-type="pmid">10837170</pub-id></element-citation></ref><ref id="b0045"><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>J.J.</given-names></name><name><surname>Wipf</surname><given-names>G.C.</given-names></name><name><surname>Benki</surname><given-names>S.F.</given-names></name><name><surname>Christensen</surname><given-names>N.D.</given-names></name><name><surname>Galloway</surname><given-names>D.A.</given-names></name></person-group><article-title>Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1</article-title><source>J. Virol.</source><volume>77</volume><year>2003</year><fpage>11625</fpage><lpage>11632</lpage><pub-id pub-id-type="pmid">14557648</pub-id></element-citation></ref><ref id="b0050"><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>J.J.</given-names></name><name><surname>Wipf</surname><given-names>G.C.</given-names></name><name><surname>Madeleine</surname><given-names>M.M.</given-names></name><name><surname>Schwartz</surname><given-names>S.M.</given-names></name><name><surname>Koutsky</surname><given-names>L.A.</given-names></name><name><surname>Galloway</surname><given-names>D.A.</given-names></name></person-group><article-title>Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera</article-title><source>J. Virol.</source><volume>80</volume><year>2006</year><fpage>4664</fpage><lpage>4672</lpage><pub-id pub-id-type="pmid">16641259</pub-id></element-citation></ref><ref id="b0055"><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.S.</given-names></name><name><surname>Garcea</surname><given-names>R.L.</given-names></name><name><surname>Goldberg</surname><given-names>I.</given-names></name><name><surname>Casini</surname><given-names>G.</given-names></name><name><surname>Harrison</surname><given-names>S.C.</given-names></name></person-group><article-title>Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16</article-title><source>Mol. Cell</source><volume>5</volume><year>2000</year><fpage>557</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">10882140</pub-id></element-citation></ref><ref id="b0060"><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>DeSalle</surname><given-names>R.</given-names></name><name><surname>Schiffman</surname><given-names>M.</given-names></name><name><surname>Herrero</surname><given-names>R.</given-names></name><name><surname>Burk</surname><given-names>R.D.</given-names></name></person-group><article-title>Evolutionary dynamics of variant genomes of human papillomavirus types 18, 45, and 97</article-title><source>J. Virol.</source><volume>83</volume><year>2009</year><fpage>1443</fpage><lpage>1455</lpage><pub-id pub-id-type="pmid">19036820</pub-id></element-citation></ref><ref id="b0065"><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Schiffman</surname><given-names>M.</given-names></name><name><surname>Herrero</surname><given-names>R.</given-names></name><name><surname>Desalle</surname><given-names>R.</given-names></name><name><surname>Anastos</surname><given-names>K.</given-names></name><name><surname>Segondy</surname><given-names>M.</given-names></name><name><surname>Sahasrabuddhe</surname><given-names>V.V.</given-names></name><name><surname>Gravitt</surname><given-names>P.E.</given-names></name><name><surname>Hsing</surname><given-names>A.W.</given-names></name><name><surname>Burk</surname><given-names>R.D.</given-names></name></person-group><article-title>Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67</article-title><source>PLoS One</source><volume>6</volume><year>2011</year><fpage>e20183</fpage><pub-id pub-id-type="pmid">21673791</pub-id></element-citation></ref><ref id="b0070"><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>G.</given-names></name><name><surname>Icenogle</surname><given-names>J.P.</given-names></name><name><surname>Kirnbauer</surname><given-names>R.</given-names></name><name><surname>Hubbert</surname><given-names>N.L.</given-names></name><name><surname>St Louis</surname><given-names>M.E.</given-names></name><name><surname>Han</surname><given-names>C.</given-names></name><name><surname>Svare</surname><given-names>E.I.</given-names></name><name><surname>Kjaer</surname><given-names>S.K.</given-names></name><name><surname>Lowy</surname><given-names>D.R.</given-names></name><name><surname>Schiller</surname><given-names>J.T.</given-names></name></person-group><article-title>Divergent human papillomavirus type 16 variants are serologically cross-reactive</article-title><source>J. Infect. Dis.</source><volume>172</volume><year>1995</year><fpage>1584</fpage><lpage>1587</lpage><pub-id pub-id-type="pmid">7594721</pub-id></element-citation></ref><ref id="b0075"><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name><surname>de Villiers</surname><given-names>E.M.</given-names></name><name><surname>Fauquet</surname><given-names>C.</given-names></name><name><surname>Broker</surname><given-names>T.R.</given-names></name><name><surname>Bernard</surname><given-names>H.U.</given-names></name><name><surname>zur Hausen</surname><given-names>H.</given-names></name></person-group><article-title>Classification of papillomaviruses</article-title><source>Virology</source><volume>324</volume><year>2004</year><fpage>17</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">15183049</pub-id></element-citation></ref><ref id="b0080"><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name><surname>Deschuyteneer</surname><given-names>M.</given-names></name><name><surname>Elouahabi</surname><given-names>A.</given-names></name><name><surname>Plainchamp</surname><given-names>D.</given-names></name><name><surname>Plisnier</surname><given-names>M.</given-names></name><name><surname>Soete</surname><given-names>D.</given-names></name><name><surname>Corazza</surname><given-names>Y.</given-names></name><name><surname>Lockman</surname><given-names>L.</given-names></name><name><surname>Giannini</surname><given-names>S.</given-names></name><name><surname>Deschamps</surname><given-names>M.</given-names></name></person-group><article-title>Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine</article-title><source>Hum. Vaccine</source><volume>6</volume><year>2010</year><fpage>407</fpage><lpage>419</lpage></element-citation></ref><ref id="b0085"><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name><surname>Dias</surname><given-names>D.</given-names></name><name><surname>Van Doren</surname><given-names>J.</given-names></name><name><surname>Schlottmann</surname><given-names>S.</given-names></name><name><surname>Kelly</surname><given-names>S.</given-names></name><name><surname>Puchalski</surname><given-names>D.</given-names></name><name><surname>Ruiz</surname><given-names>W.</given-names></name><name><surname>Boerckel</surname><given-names>P.</given-names></name><name><surname>Kessler</surname><given-names>J.</given-names></name><name><surname>Antonello</surname><given-names>J.M.</given-names></name><name><surname>Green</surname><given-names>T.</given-names></name><name><surname>Brown</surname><given-names>M.</given-names></name><name><surname>Smith</surname><given-names>J.</given-names></name><name><surname>Chirmule</surname><given-names>N.</given-names></name><name><surname>Barr</surname><given-names>E.</given-names></name><name><surname>Jansen</surname><given-names>K.U.</given-names></name><name><surname>Esser</surname><given-names>M.T.</given-names></name></person-group><article-title>Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18</article-title><source>Clin. Diagn. Lab. Immunol.</source><volume>12</volume><year>2005</year><fpage>959</fpage><lpage>969</lpage><pub-id pub-id-type="pmid">16085914</pub-id></element-citation></ref><ref id="b0090"><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name><surname>Draper</surname><given-names>E.</given-names></name><name><surname>Bissett</surname><given-names>S.L.</given-names></name><name><surname>Howell-Jones</surname><given-names>R.</given-names></name><name><surname>Edwards</surname><given-names>D.</given-names></name><name><surname>Munslow</surname><given-names>G.</given-names></name><name><surname>Soldan</surname><given-names>K.</given-names></name><name><surname>Beddows</surname><given-names>S.</given-names></name></person-group><article-title>Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera</article-title><source>Vaccine</source><volume>29</volume><year>2011</year><fpage>8585</fpage><lpage>8590</lpage><pub-id pub-id-type="pmid">21939712</pub-id></element-citation></ref><ref id="b0095"><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name><surname>Einstein</surname><given-names>M.H.</given-names></name><name><surname>Baron</surname><given-names>M.</given-names></name><name><surname>Levin</surname><given-names>M.J.</given-names></name><name><surname>Chatterjee</surname><given-names>A.</given-names></name><name><surname>Edwards</surname><given-names>R.P.</given-names></name><name><surname>Zepp</surname><given-names>F.</given-names></name><name><surname>Carletti</surname><given-names>I.</given-names></name><name><surname>Dessy</surname><given-names>F.J.</given-names></name><name><surname>Trofa</surname><given-names>A.F.</given-names></name><name><surname>Schuind</surname><given-names>A.</given-names></name><name><surname>Dubin</surname><given-names>G.</given-names></name></person-group><article-title>Comparison of the immunogenicity and safety of cervarix and gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years</article-title><source>Hum. Vaccine</source><volume>5</volume><year>2009</year><fpage>705</fpage><lpage>719</lpage></element-citation></ref><ref id="b0100"><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name><surname>Einstein</surname><given-names>M.H.</given-names></name><name><surname>Baron</surname><given-names>M.</given-names></name><name><surname>Levin</surname><given-names>M.J.</given-names></name><name><surname>Chatterjee</surname><given-names>A.</given-names></name><name><surname>Fox</surname><given-names>B.</given-names></name><name><surname>Scholar</surname><given-names>S.</given-names></name><name><surname>Rosen</surname><given-names>J.</given-names></name><name><surname>Chakhtoura</surname><given-names>N.</given-names></name><name><surname>Lebacq</surname><given-names>M.</given-names></name><name><surname>van der Most</surname><given-names>R.</given-names></name><name><surname>Moris</surname><given-names>P.</given-names></name><name><surname>Giannini</surname><given-names>S.L.</given-names></name><name><surname>Schuind</surname><given-names>A.</given-names></name><name><surname>Datta</surname><given-names>S.K.</given-names></name><name><surname>Descamps</surname><given-names>D.</given-names></name></person-group><article-title>Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years</article-title><source>Hum. Vaccine</source><volume>7</volume><year>2011</year><fpage>1359</fpage><lpage>1373</lpage></element-citation></ref><ref id="b0105"><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name><surname>Fleury</surname><given-names>M.J.</given-names></name><name><surname>Touze</surname><given-names>A.</given-names></name><name><surname>Maurel</surname><given-names>M.C.</given-names></name><name><surname>Moreau</surname><given-names>T.</given-names></name><name><surname>Coursaget</surname><given-names>P.</given-names></name></person-group><article-title>Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications</article-title><source>Protein Sci.</source><volume>18</volume><year>2009</year><fpage>1425</fpage><lpage>1438</lpage><pub-id pub-id-type="pmid">19533761</pub-id></element-citation></ref><ref id="b0110"><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name><surname>Giannini</surname><given-names>S.L.</given-names></name><name><surname>Hanon</surname><given-names>E.</given-names></name><name><surname>Moris</surname><given-names>P.</given-names></name><name><surname>Van Mechelen</surname><given-names>M.</given-names></name><name><surname>Morel</surname><given-names>S.</given-names></name><name><surname>Dessy</surname><given-names>F.</given-names></name><name><surname>Fourneau</surname><given-names>M.A.</given-names></name><name><surname>Colau</surname><given-names>B.</given-names></name><name><surname>Suzich</surname><given-names>J.</given-names></name><name><surname>Losonksy</surname><given-names>G.</given-names></name><name><surname>Martin</surname><given-names>M.T.</given-names></name><name><surname>Dubin</surname><given-names>G.</given-names></name><name><surname>Wettendorff</surname><given-names>M.A.</given-names></name></person-group><article-title>Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only</article-title><source>Vaccine</source><volume>24</volume><year>2006</year><fpage>5937</fpage><lpage>5949</lpage><pub-id pub-id-type="pmid">16828940</pub-id></element-citation></ref><ref id="b0115"><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name><surname>Guex</surname><given-names>N.</given-names></name><name><surname>Peitsch</surname><given-names>M.C.</given-names></name></person-group><article-title>SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling</article-title><source>Electrophoresis</source><volume>18</volume><year>1997</year><fpage>2714</fpage><lpage>2723</lpage><pub-id pub-id-type="pmid">9504803</pub-id></element-citation></ref><ref id="b0120"><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J.W.</given-names></name><name><surname>Lin</surname><given-names>W.F.</given-names></name><name><surname>Yang</surname><given-names>J.M.</given-names></name></person-group><article-title>Antigenic sites of H1N1 influenza virus hemagglutinin revealed by natural isolates and inhibition assays</article-title><source>Vaccine</source><volume>30</volume><year>2012</year><fpage>6327</fpage><lpage>6337</lpage><pub-id pub-id-type="pmid">22885274</pub-id></element-citation></ref><ref id="b0125"><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>X.H.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>H.Y.</given-names></name><name><surname>Cheng</surname><given-names>W.X.</given-names></name><name><surname>Liu</surname><given-names>N.</given-names></name><name><surname>Tan</surname><given-names>M.</given-names></name><name><surname>Jiang</surname><given-names>T.</given-names></name><name><surname>Duan</surname><given-names>Z.J.</given-names></name></person-group><article-title>Genetic diversity of noroviruses in Chinese adults: potential recombination hotspots and GII-4/Den Haag-specific mutations at a putative epitope</article-title><source>Infect. Genet. Evol.</source><volume>11</volume><year>2011</year><fpage>1716</fpage><lpage>1726</lpage><pub-id pub-id-type="pmid">21803173</pub-id></element-citation></ref><ref id="b0130"><element-citation publication-type="journal" id="h0130"><person-group person-group-type="author"><name><surname>Kemp</surname><given-names>T.J.</given-names></name><name><surname>Hildesheim</surname><given-names>A.</given-names></name><name><surname>Safaeian</surname><given-names>M.</given-names></name><name><surname>Dauner</surname><given-names>J.G.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Porras</surname><given-names>C.</given-names></name><name><surname>Schiller</surname><given-names>J.T.</given-names></name><name><surname>Lowy</surname><given-names>D.R.</given-names></name><name><surname>Herrero</surname><given-names>R.</given-names></name><name><surname>Pinto</surname><given-names>L.A.</given-names></name></person-group><article-title>HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection</article-title><source>Vaccine</source><volume>29</volume><year>2011</year><fpage>2011</fpage><lpage>2014</lpage><pub-id pub-id-type="pmid">21241731</pub-id></element-citation></ref><ref id="b0135"><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name><surname>Knappe</surname><given-names>M.</given-names></name><name><surname>Bodevin</surname><given-names>S.</given-names></name><name><surname>Selinka</surname><given-names>H.C.</given-names></name><name><surname>Spillmann</surname><given-names>D.</given-names></name><name><surname>Streeck</surname><given-names>R.E.</given-names></name><name><surname>Chen</surname><given-names>X.S.</given-names></name><name><surname>Lindahl</surname><given-names>U.</given-names></name><name><surname>Sapp</surname><given-names>M.</given-names></name></person-group><article-title>Surface-exposed amino acid residues of HPV16 L1 protein mediating interaction with cell surface heparan sulfate</article-title><source>J. Biol. Chem.</source><volume>282</volume><year>2007</year><fpage>27913</fpage><lpage>27922</lpage><pub-id pub-id-type="pmid">17640876</pub-id></element-citation></ref><ref id="b0140"><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name><surname>Korber</surname><given-names>B.T.</given-names></name><name><surname>Kunstman</surname><given-names>K.J.</given-names></name><name><surname>Patterson</surname><given-names>B.K.</given-names></name><name><surname>Furtado</surname><given-names>M.</given-names></name><name><surname>McEvilly</surname><given-names>M.M.</given-names></name><name><surname>Levy</surname><given-names>R.</given-names></name><name><surname>Wolinsky</surname><given-names>S.M.</given-names></name></person-group><article-title>Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences</article-title><source>J. Virol.</source><volume>68</volume><year>1994</year><fpage>7467</fpage><lpage>7481</lpage><pub-id pub-id-type="pmid">7933130</pub-id></element-citation></ref><ref id="b0145"><element-citation publication-type="journal" id="h0145"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N.</given-names></name><name><surname>Franceschi</surname><given-names>S.</given-names></name><name><surname>Howell-Jones</surname><given-names>R.</given-names></name><name><surname>Snijders</surname><given-names>P.J.</given-names></name><name><surname>Clifford</surname><given-names>G.M.</given-names></name></person-group><article-title>Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication</article-title><source>Int. J. Cancer</source><volume>128</volume><year>2010</year><fpage>927</fpage><lpage>935</lpage><pub-id pub-id-type="pmid">20473886</pub-id></element-citation></ref><ref id="b0150"><element-citation publication-type="journal" id="h0150"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>S.W.</given-names></name><name><surname>Ghosh</surname><given-names>A.</given-names></name><name><surname>Porras</surname><given-names>C.</given-names></name><name><surname>Markt</surname><given-names>S.C.</given-names></name><name><surname>Rodriguez</surname><given-names>A.C.</given-names></name><name><surname>Schiffman</surname><given-names>M.</given-names></name><name><surname>Wacholder</surname><given-names>S.</given-names></name><name><surname>Kemp</surname><given-names>T.J.</given-names></name><name><surname>Pinto</surname><given-names>L.A.</given-names></name><name><surname>Gonzalez</surname><given-names>P.</given-names></name><name><surname>Wentzensen</surname><given-names>N.</given-names></name><name><surname>Esser</surname><given-names>M.T.</given-names></name><name><surname>Matys</surname><given-names>K.</given-names></name><name><surname>Meuree</surname><given-names>A.</given-names></name><name><surname>Quint</surname><given-names>W.</given-names></name><name><surname>van Doorn</surname><given-names>L.J.</given-names></name><name><surname>Herrero</surname><given-names>R.</given-names></name><name><surname>Hildesheim</surname><given-names>A.</given-names></name><name><surname>Safaeian</surname><given-names>M.</given-names></name></person-group><article-title>HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><fpage>e53067</fpage><pub-id pub-id-type="pmid">23301022</pub-id></element-citation></ref><ref id="b0155"><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name><surname>Longet</surname><given-names>S.</given-names></name><name><surname>Schiller</surname><given-names>J.T.</given-names></name><name><surname>Bobst</surname><given-names>M.</given-names></name><name><surname>Jichlinski</surname><given-names>P.</given-names></name><name><surname>Nardelli-Haefliger</surname><given-names>D.</given-names></name></person-group><article-title>A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection</article-title><source>J. Virol.</source><volume>85</volume><year>2011</year><fpage>13253</fpage><lpage>13259</lpage><pub-id pub-id-type="pmid">21976653</pub-id></element-citation></ref><ref id="b0160"><element-citation publication-type="journal" id="h0160"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>B.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Castellsague</surname><given-names>X.</given-names></name><name><surname>Giuliano</surname><given-names>A.R.</given-names></name></person-group><article-title>Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review and meta-analysis</article-title><source>BMC Infect. Dis.</source><volume>11</volume><year>2011</year><fpage>13</fpage><pub-id pub-id-type="pmid">21226933</pub-id></element-citation></ref><ref id="b0165"><element-citation publication-type="journal" id="h0165"><person-group person-group-type="author"><name><surname>Ludmerer</surname><given-names>S.W.</given-names></name><name><surname>Benincasa</surname><given-names>D.</given-names></name><name><surname>Mark</surname><given-names>G.E.</given-names><suffix>3rd</suffix></name></person-group><article-title>Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11</article-title><source>J. Virol.</source><volume>70</volume><year>1996</year><fpage>4791</fpage><lpage>4794</lpage><pub-id pub-id-type="pmid">8676509</pub-id></element-citation></ref><ref id="b0170"><element-citation publication-type="journal" id="h0170"><person-group person-group-type="author"><name><surname>McClements</surname><given-names>W.L.</given-names></name><name><surname>Wang</surname><given-names>X.M.</given-names></name><name><surname>Ling</surname><given-names>J.C.</given-names></name><name><surname>Skulsky</surname><given-names>D.M.</given-names></name><name><surname>Christensen</surname><given-names>N.D.</given-names></name><name><surname>Jansen</surname><given-names>K.U.</given-names></name><name><surname>Ludmerer</surname><given-names>S.W.</given-names></name></person-group><article-title>A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1</article-title><source>Virology</source><volume>289</volume><year>2001</year><fpage>262</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">11689049</pub-id></element-citation></ref><ref id="b0175"><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name><surname>Munoz</surname><given-names>N.</given-names></name><name><surname>Kjaer</surname><given-names>S.K.</given-names></name><name><surname>Sigurdsson</surname><given-names>K.</given-names></name><name><surname>Iversen</surname><given-names>O.E.</given-names></name><name><surname>Hernandez-Avila</surname><given-names>M.</given-names></name><name><surname>Wheeler</surname><given-names>C.M.</given-names></name><name><surname>Perez</surname><given-names>G.</given-names></name><name><surname>Brown</surname><given-names>D.R.</given-names></name><name><surname>Koutsky</surname><given-names>L.A.</given-names></name><name><surname>Tay</surname><given-names>E.H.</given-names></name><name><surname>Garcia</surname><given-names>P.J.</given-names></name><name><surname>Ault</surname><given-names>K.A.</given-names></name><name><surname>Garland</surname><given-names>S.M.</given-names></name><name><surname>Leodolter</surname><given-names>S.</given-names></name><name><surname>Olsson</surname><given-names>S.E.</given-names></name><name><surname>Tang</surname><given-names>G.W.</given-names></name><name><surname>Ferris</surname><given-names>D.G.</given-names></name><name><surname>Paavonen</surname><given-names>J.</given-names></name><name><surname>Steben</surname><given-names>M.</given-names></name><name><surname>Bosch</surname><given-names>F.X.</given-names></name><name><surname>Dillner</surname><given-names>J.</given-names></name><name><surname>Huh</surname><given-names>W.K.</given-names></name><name><surname>Joura</surname><given-names>E.A.</given-names></name><name><surname>Kurman</surname><given-names>R.J.</given-names></name><name><surname>Majewski</surname><given-names>S.</given-names></name><name><surname>Myers</surname><given-names>E.R.</given-names></name><name><surname>Villa</surname><given-names>L.L.</given-names></name><name><surname>Taddeo</surname><given-names>F.J.</given-names></name><name><surname>Roberts</surname><given-names>C.</given-names></name><name><surname>Tadesse</surname><given-names>A.</given-names></name><name><surname>Bryan</surname><given-names>J.T.</given-names></name><name><surname>Lupinacci</surname><given-names>L.C.</given-names></name><name><surname>Giacoletti</surname><given-names>K.E.</given-names></name><name><surname>Sings</surname><given-names>H.L.</given-names></name><name><surname>James</surname><given-names>M.K.</given-names></name><name><surname>Hesley</surname><given-names>T.M.</given-names></name><name><surname>Barr</surname><given-names>E.</given-names></name><name><surname>Haupt</surname><given-names>R.M.</given-names></name></person-group><article-title>Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women</article-title><source>J. Natl. Cancer Inst.</source><volume>102</volume><year>2010</year><fpage>325</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">20139221</pub-id></element-citation></ref><ref id="b0180"><element-citation publication-type="book" id="h0180"><person-group person-group-type="author"><name><surname>Myers</surname><given-names>G.</given-names></name><name><surname>Delius</surname><given-names>H.</given-names></name><name><surname>Icenogle</surname><given-names>J.</given-names></name><name><surname>Bernard</surname><given-names>H.U.</given-names></name><name><surname>Baker</surname><given-names>C.</given-names></name><name><surname>Halpern</surname><given-names>A.</given-names></name><name><surname>Wheeler</surname><given-names>C.</given-names></name></person-group><chapter-title>Human Papillomaviruses 1995: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences</chapter-title><year>1995</year><publisher-name>Theoretical Biology and Biophysics</publisher-name><publisher-loc>Los Alamos National Laboratory, Los Alamos, NM</publisher-loc></element-citation></ref><ref id="b0185"><element-citation publication-type="journal" id="h0185"><person-group person-group-type="author"><name><surname>Orozco</surname><given-names>J.J.</given-names></name><name><surname>Carter</surname><given-names>J.J.</given-names></name><name><surname>Koutsky</surname><given-names>L.A.</given-names></name><name><surname>Galloway</surname><given-names>D.A.</given-names></name></person-group><article-title>Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers</article-title><source>J. Virol.</source><volume>79</volume><year>2005</year><fpage>9503</fpage><lpage>9514</lpage><pub-id pub-id-type="pmid">16014913</pub-id></element-citation></ref><ref id="b0190"><element-citation publication-type="journal" id="h0190"><person-group person-group-type="author"><name><surname>Paavonen</surname><given-names>J.</given-names></name><name><surname>Jenkins</surname><given-names>D.</given-names></name><name><surname>Bosch</surname><given-names>F.X.</given-names></name><name><surname>Naud</surname><given-names>P.</given-names></name><name><surname>Salmeron</surname><given-names>J.</given-names></name><name><surname>Wheeler</surname><given-names>C.M.</given-names></name><name><surname>Chow</surname><given-names>S.N.</given-names></name><name><surname>Apter</surname><given-names>D.L.</given-names></name><name><surname>Kitchener</surname><given-names>H.C.</given-names></name><name><surname>Castellsague</surname><given-names>X.</given-names></name><name><surname>de Carvalho</surname><given-names>N.S.</given-names></name><name><surname>Skinner</surname><given-names>S.R.</given-names></name><name><surname>Harper</surname><given-names>D.M.</given-names></name><name><surname>Hedrick</surname><given-names>J.A.</given-names></name><name><surname>Jaisamrarn</surname><given-names>U.</given-names></name><name><surname>Limson</surname><given-names>G.A.</given-names></name><name><surname>Dionne</surname><given-names>M.</given-names></name><name><surname>Quint</surname><given-names>W.</given-names></name><name><surname>Spiessens</surname><given-names>B.</given-names></name><name><surname>Peeters</surname><given-names>P.</given-names></name><name><surname>Struyf</surname><given-names>F.</given-names></name><name><surname>Wieting</surname><given-names>S.L.</given-names></name><name><surname>Lehtinen</surname><given-names>M.O.</given-names></name><name><surname>Dubin</surname><given-names>G.</given-names></name></person-group><article-title>Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial</article-title><source>Lancet</source><volume>369</volume><year>2007</year><fpage>2161</fpage><lpage>2170</lpage><pub-id pub-id-type="pmid">17602732</pub-id></element-citation></ref><ref id="b0195"><element-citation publication-type="journal" id="h0195"><person-group person-group-type="author"><name><surname>Pastrana</surname><given-names>D.V.</given-names></name><name><surname>Buck</surname><given-names>C.B.</given-names></name><name><surname>Pang</surname><given-names>Y.Y.</given-names></name><name><surname>Thompson</surname><given-names>C.D.</given-names></name><name><surname>Castle</surname><given-names>P.E.</given-names></name><name><surname>FitzGerald</surname><given-names>P.C.</given-names></name><name><surname>Kruger Kjaer</surname><given-names>S.</given-names></name><name><surname>Lowy</surname><given-names>D.R.</given-names></name><name><surname>Schiller</surname><given-names>J.T.</given-names></name></person-group><article-title>Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18</article-title><source>Virology</source><volume>321</volume><year>2004</year><fpage>205</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">15051381</pub-id></element-citation></ref><ref id="b0200"><element-citation publication-type="journal" id="h0200"><person-group person-group-type="author"><name><surname>Pastrana</surname><given-names>D.V.</given-names></name><name><surname>Vass</surname><given-names>W.C.</given-names></name><name><surname>Lowy</surname><given-names>D.R.</given-names></name><name><surname>Schiller</surname><given-names>J.T.</given-names></name></person-group><article-title>NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16</article-title><source>Virology</source><volume>279</volume><year>2001</year><fpage>361</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">11145917</pub-id></element-citation></ref><ref id="b0205"><element-citation publication-type="journal" id="h0205"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>S.Y.</given-names></name><name><surname>Liu</surname><given-names>T.F.</given-names></name><name><surname>Kiuchi</surname><given-names>M.</given-names></name><name><surname>Zioni</surname><given-names>R.</given-names></name><name><surname>Gifford</surname><given-names>R.J.</given-names></name><name><surname>Holmes</surname><given-names>S.P.</given-names></name><name><surname>Shafer</surname><given-names>R.W.</given-names></name></person-group><article-title>Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors</article-title><source>Retrovirology</source><volume>5</volume><year>2008</year><fpage>74</fpage><pub-id pub-id-type="pmid">18687142</pub-id></element-citation></ref><ref id="b0210"><element-citation publication-type="journal" id="h0210"><person-group person-group-type="author"><name><surname>Rizk</surname><given-names>R.Z.</given-names></name><name><surname>Christensen</surname><given-names>N.D.</given-names></name><name><surname>Michael</surname><given-names>K.M.</given-names></name><name><surname>Muller</surname><given-names>M.</given-names></name><name><surname>Sehr</surname><given-names>P.</given-names></name><name><surname>Waterboer</surname><given-names>T.</given-names></name><name><surname>Pawlita</surname><given-names>M.</given-names></name></person-group><article-title>Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types</article-title><source>J. Gen. Virol.</source><volume>89</volume><year>2008</year><fpage>117</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">18089735</pub-id></element-citation></ref><ref id="b0215"><element-citation publication-type="journal" id="h0215"><person-group person-group-type="author"><name><surname>Roden</surname><given-names>R.B.</given-names></name><name><surname>Armstrong</surname><given-names>A.</given-names></name><name><surname>Haderer</surname><given-names>P.</given-names></name><name><surname>Christensen</surname><given-names>N.D.</given-names></name><name><surname>Hubbert</surname><given-names>N.L.</given-names></name><name><surname>Lowy</surname><given-names>D.R.</given-names></name><name><surname>Schiller</surname><given-names>J.T.</given-names></name><name><surname>Kirnbauer</surname><given-names>R.</given-names></name></person-group><article-title>Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope</article-title><source>J. Virol.</source><volume>71</volume><year>1997</year><fpage>6247</fpage><lpage>6252</lpage><pub-id pub-id-type="pmid">9223527</pub-id></element-citation></ref><ref id="b0220"><element-citation publication-type="journal" id="h0220"><person-group person-group-type="author"><name><surname>Romanowski</surname><given-names>B.</given-names></name></person-group><article-title>Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines</article-title><source>Hum. Vaccine</source><volume>7</volume><year>2011</year><fpage>161</fpage><lpage>169</lpage></element-citation></ref><ref id="b0225"><element-citation publication-type="journal" id="h0225"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>S.D.</given-names></name><name><surname>Sapp</surname><given-names>M.</given-names></name><name><surname>Streeck</surname><given-names>R.E.</given-names></name><name><surname>Selinka</surname><given-names>H.C.</given-names></name></person-group><article-title>Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33</article-title><source>Virol. J.</source><volume>3</volume><year>2006</year><fpage>83</fpage><pub-id pub-id-type="pmid">17014700</pub-id></element-citation></ref><ref id="b0230"><element-citation publication-type="journal" id="h0230"><person-group person-group-type="author"><name><surname>Schiller</surname><given-names>J.T.</given-names></name><name><surname>Castellsague</surname><given-names>X.</given-names></name><name><surname>Garland</surname><given-names>S.M.</given-names></name></person-group><article-title>A review of clinical trials of human papillomavirus prophylactic vaccines</article-title><source>Vaccine</source><volume>30</volume><issue>Suppl. 5</issue><year>2012</year><fpage>F123</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">23199956</pub-id></element-citation></ref><ref id="b0235"><element-citation publication-type="journal" id="h0235"><person-group person-group-type="author"><name><surname>Schiller</surname><given-names>J.T.</given-names></name><name><surname>Lowy</surname><given-names>D.R.</given-names></name></person-group><article-title>Understanding and learning from the success of prophylactic human papillomavirus vaccines</article-title><source>Nat. Rev. Microbiol.</source><volume>10</volume><year>2012</year><fpage>681</fpage><lpage>692</lpage><pub-id pub-id-type="pmid">22961341</pub-id></element-citation></ref><ref id="b0240"><element-citation publication-type="journal" id="h0240"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>J.F.</given-names></name><name><surname>Brownlow</surname><given-names>M.</given-names></name><name><surname>Brown</surname><given-names>M.</given-names></name><name><surname>Kowalski</surname><given-names>R.</given-names></name><name><surname>Esser</surname><given-names>M.T.</given-names></name><name><surname>Ruiz</surname><given-names>W.</given-names></name><name><surname>Barr</surname><given-names>E.</given-names></name><name><surname>Brown</surname><given-names>D.R.</given-names></name><name><surname>Bryan</surname><given-names>J.T.</given-names></name></person-group><article-title>Antibodies from women immunized with gardasil ((R)) cross-neutralize HPV 45 pseudovirions</article-title><source>Hum. Vaccines</source><volume>3</volume><year>2007</year><fpage>109</fpage><lpage>116</lpage></element-citation></ref><ref id="b0245"><element-citation publication-type="journal" id="h0245"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>J.F.</given-names></name><name><surname>Kowalski</surname><given-names>R.</given-names></name><name><surname>Esser</surname><given-names>M.T.</given-names></name><name><surname>Brown</surname><given-names>M.J.</given-names></name><name><surname>Bryan</surname><given-names>J.T.</given-names></name></person-group><article-title>Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11</article-title><source>Hum. Vaccine</source><volume>4</volume><year>2008</year><fpage>134</fpage><lpage>142</lpage></element-citation></ref><ref id="b0250"><element-citation publication-type="journal" id="h0250"><person-group person-group-type="author"><name><surname>Tamura</surname><given-names>K.</given-names></name><name><surname>Dudley</surname><given-names>J.</given-names></name><name><surname>Nei</surname><given-names>M.</given-names></name><name><surname>Kumar</surname><given-names>S.</given-names></name></person-group><article-title>MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0</article-title><source>Mol. Biol. Evol.</source><volume>24</volume><year>2007</year><fpage>1596</fpage><lpage>1599</lpage><pub-id pub-id-type="pmid">17488738</pub-id></element-citation></ref><ref id="b0255"><element-citation publication-type="journal" id="h0255"><person-group person-group-type="author"><name><surname>Touze</surname><given-names>A.</given-names></name><name><surname>El Mehdaoui</surname><given-names>S.</given-names></name><name><surname>Sizaret</surname><given-names>P.Y.</given-names></name><name><surname>Mougin</surname><given-names>C.</given-names></name><name><surname>Munoz</surname><given-names>N.</given-names></name><name><surname>Coursaget</surname><given-names>P.</given-names></name></person-group><article-title>The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system</article-title><source>J. Clin. Microbiol.</source><volume>36</volume><year>1998</year><fpage>2046</fpage><lpage>2051</lpage><pub-id pub-id-type="pmid">9650960</pub-id></element-citation></ref><ref id="b0260"><element-citation publication-type="journal" id="h0260"><person-group person-group-type="author"><name><surname>Van de Velde</surname><given-names>N.</given-names></name><name><surname>Boily</surname><given-names>M.C.</given-names></name><name><surname>Drolet</surname><given-names>M.</given-names></name><name><surname>Franco</surname><given-names>E.L.</given-names></name><name><surname>Mayrand</surname><given-names>M.H.</given-names></name><name><surname>Kliewer</surname><given-names>E.V.</given-names></name><name><surname>Coutlee</surname><given-names>F.</given-names></name><name><surname>Laprise</surname><given-names>J.F.</given-names></name><name><surname>Malagon</surname><given-names>T.</given-names></name><name><surname>Brisson</surname><given-names>M.</given-names></name></person-group><article-title>Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis</article-title><source>J. Natl. Cancer Inst.</source><volume>104</volume><year>2012</year><fpage>1712</fpage><lpage>1723</lpage><pub-id pub-id-type="pmid">23104323</pub-id></element-citation></ref><ref id="b0265"><element-citation publication-type="journal" id="h0265"><person-group person-group-type="author"><name><surname>Varsani</surname><given-names>A.</given-names></name><name><surname>Williamson</surname><given-names>A.L.</given-names></name><name><surname>Jaffer</surname><given-names>M.A.</given-names></name><name><surname>Rybicki</surname><given-names>E.P.</given-names></name></person-group><article-title>A deletion and point mutation study of the human papillomavirus type 16 major capsid gene</article-title><source>Virus Res.</source><volume>122</volume><year>2006</year><fpage>154</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">16938363</pub-id></element-citation></ref><ref id="b0270"><element-citation publication-type="journal" id="h0270"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Christensen</surname><given-names>N.D.</given-names></name><name><surname>Dillner</surname><given-names>J.</given-names></name></person-group><article-title>Mapping of human serum-reactive epitopes in virus-like particles of human papillomavirus types 16 and 11</article-title><source>Virology</source><volume>311</volume><year>2003</year><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">12832218</pub-id></element-citation></ref><ref id="b0275"><element-citation publication-type="journal" id="h0275"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Christensen</surname><given-names>N.</given-names></name><name><surname>Schiller</surname><given-names>J.T.</given-names></name><name><surname>Dillner</surname><given-names>J.</given-names></name></person-group><article-title>A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera</article-title><source>J. Gen. Virol.</source><volume>78</volume><year>1997</year><fpage>2209</fpage><lpage>2215</lpage><pub-id pub-id-type="pmid">9292008</pub-id></element-citation></ref><ref id="b0280"><element-citation publication-type="journal" id="h0280"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>J.</given-names></name><name><surname>Robertson</surname><given-names>D.L.</given-names></name><name><surname>Lovell</surname><given-names>S.C.</given-names></name></person-group><article-title>Constraints on HIV-1 diversity from protein structure</article-title><source>J. Virol.</source><volume>84</volume><year>2010</year><fpage>12995</fpage><lpage>13003</lpage><pub-id pub-id-type="pmid">20881050</pub-id></element-citation></ref></ref-list><sec id="s0065" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p><supplementary-material content-type="local-data" id="m0005"><caption><title>Supplementary Fig. S1</title><p>Coincidence of major variant residues for genotypes within the A9 and A7 species groups.Amino acid residue numbering and reference sequence shown for each genotype with percentage occurence of each variant in the dataset indicated below. For clarity, only those residue positions that vary individually at or above the 5% diversity threshold are shown. [N], number in parentheses highlight the total number of sequences included for indicated HPV genotype.</p></caption><media xlink:href="mmc1.pdf"></media></supplementary-material><supplementary-material content-type="local-data" id="m0010"><caption><title>Supplementary Fig. S2</title><p>Inter-type, site-specific amino acid residue entropy. Residue variation estimated using Shannon entropy, wherein a value of zero reflects site-specific conservation and higher values indicate increasing degrees of site-specific variation. The positions of major structural elements are indicated.</p></caption><media xlink:href="mmc2.pdf"></media></supplementary-material><supplementary-material content-type="local-data" id="m0015"><caption><title>Supplementary Table S1</title><p>Accession numbers and source references.</p></caption><media xlink:href="mmc3.pdf"></media></supplementary-material></p></sec><ack id="ak005"><title>Acknowledgements</title><p>We thank Drs. Steve Platt and Richard Myers for helpful discussion. AIA was a Master’s project student from the London School of Hygiene and Tropical Medicine.</p></ack><fn-group><fn id="d32e1209"><label>☆</label><p>This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.</p></fn><fn id="s0060" fn-type="supplementary-material"><label>Appendix A</label><p>Supplementary data associated with this article can be found, in the online version, at <ext-link ext-link-type="doi" xlink:href="10.1016/j.meegid.2013.05.013" id="ir0015">http://dx.doi.org/10.1016/j.meegid.2013.05.013</ext-link>.</p></fn></fn-group></back><floats-group><fig id="f0005"><label>Fig. 1</label><caption><p>Geographical distribution of HPV full length L1 sequences. Total numbers of available full length L1 sequences for each HPV type are indicated beneath each chart. Alpha-papillomavirus species groups are as indicated: A10 (HPV6, HPV11), A9 (HPV16, HPV31, HPV33, HPV52 and HPV58) and A7 (HPV18, HPV45). The regional proportion of L1 sequences are colored according to the inset map: Americas (green), Europe (yellow), Africa (blue) and Asia (red).</p></caption><graphic xlink:href="gr1"></graphic></fig><fig id="f0010"><label>Fig. 2</label><caption><p>Intra-type, site-specific amino acid residue entropy. Residue variation estimated using Shannon entropy, wherein a value of zero reflects site-specific conservation and higher values indicate increasing degrees of site-specific variation. A level of 5% residue variation equates to an entropy score of <italic>ca</italic>. 0.18. Site-specific variation(s) above this level are indicated by convention, numbered according to the reference sequence for that HPV type. The positions of major structural elements are indicated.</p></caption><graphic xlink:href="gr2"></graphic></fig><fig id="f0015"><label>Fig. 3</label><caption><p>Crystal model surface representation of variant amino acid residues. (A) top view (left panel) and side view (right panel) of HPV16 pentamer (PDB code: 2R5H) with variable loops shaded as indicated. (B) Shannon entropy scores for indicated A9 HPV types are mapped onto top view of HPV16 pentamer structure according to the indicated scheme. Only those variant amino acid residues located on the surface of the capsomer are shown. While all five monomers of the capsomer are pictured, and all appropriate sites of variation are highlighted, only one of the five copies of a residue are indicated with the amino acid mutation (black arrows), and all the variations for a given HPV type may not be indicated on the same monomer.</p></caption><graphic xlink:href="gr3"></graphic></fig><table-wrap id="t0005" position="float"><label>Table 1</label><caption><p>Summary of L1 amino acid polymorphisms.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">HPV</th><th rowspan="2">Residue</th><th rowspan="2">Region<xref rid="tblfn1" ref-type="table-fn">a</xref></th><th colspan="4">Geographical region<xref rid="tblfn2" ref-type="table-fn">b</xref><hr></hr></th><th colspan="2">Total<hr></hr></th></tr><tr><th>Americas</th><th>Europe</th><th>Africa</th><th>Asia</th><th>n/N</th><th>% (95%CI)</th></tr></thead><tbody><tr><td>6</td><td>E431Q</td><td>α4-βJ</td><td>0/2</td><td>23/131</td><td></td><td>0/3</td><td>23/136</td><td>17 (11–24)</td></tr><tr><td>11</td><td>A235S</td><td>α1</td><td>0/2</td><td>7/93</td><td></td><td>0/8</td><td>7/103</td><td>7 (3–14)</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>16</td><td>H76Y</td><td>βC</td><td>35/86</td><td>0/8</td><td><bold>16/19</bold><xref rid="tblfn3" ref-type="table-fn">⁎</xref></td><td><bold>12/70</bold><xref rid="tblfn3" ref-type="table-fn">⁎</xref></td><td>63/183</td><td>34 (28–42)</td></tr><tr><td></td><td>T176N</td><td>EF</td><td>35/86</td><td>0/8</td><td><bold>16/19</bold><xref rid="tblfn3" ref-type="table-fn">⁎</xref></td><td>13/70</td><td>64/183</td><td>35 (28–43)</td></tr><tr><td></td><td>N181T</td><td>EF</td><td>17/86</td><td>0/8</td><td>6/19</td><td>18/70</td><td>41/183</td><td>22 (17–29)</td></tr><tr><td></td><td>T266A</td><td>FG</td><td>68/86</td><td>8/8</td><td>16/19</td><td>70/70</td><td>162/183</td><td>89 (83–93)</td></tr><tr><td></td><td>S282P</td><td>FG</td><td>4/86</td><td>0/8</td><td><bold>7/19</bold><xref rid="tblfn4" ref-type="table-fn">⁎⁎</xref></td><td>2/70</td><td>13/183</td><td>7 (4–12)</td></tr><tr><td></td><td>T353P</td><td>HI</td><td>26/86</td><td>0/8</td><td>9/19</td><td>11/70</td><td>46/183</td><td>25 (19–32)</td></tr><tr><td></td><td>T389S</td><td>α2</td><td>10/86</td><td>0/8</td><td>2/19</td><td>5/70</td><td>17/183</td><td>9 (6–14)</td></tr><tr><td></td><td>L475F</td><td>Ct</td><td>34/86</td><td>0/8</td><td><bold>16/19</bold><xref rid="tblfn3" ref-type="table-fn">⁎</xref></td><td><bold>10/70</bold><xref rid="tblfn3" ref-type="table-fn">⁎</xref></td><td>60/183</td><td>33 (26–40)</td></tr><tr><td>31</td><td>T267A</td><td>FG</td><td>46/89</td><td></td><td>1/3</td><td>0/3</td><td>47/95</td><td>49 (39–60)</td></tr><tr><td></td><td>T274N</td><td>FG</td><td>71/89</td><td></td><td>2/3</td><td>1/3</td><td>74/95</td><td>78 (68–86)</td></tr><tr><td></td><td>T432S</td><td>α4-βJ</td><td>7/89</td><td></td><td>0/3</td><td>0/3</td><td>7/95</td><td>7 (3–15)</td></tr><tr><td>33</td><td>T56N</td><td>BC</td><td>18/46</td><td></td><td>3/7</td><td>4/5</td><td>25/58</td><td>43 (30–57)</td></tr><tr><td></td><td>G133S</td><td>DE</td><td>18/46</td><td></td><td>3/7</td><td>4/5</td><td>25/58</td><td>43 (30–57)</td></tr><tr><td></td><td>K135R</td><td>DE</td><td>2/46</td><td></td><td>0/7</td><td>1/5</td><td>3/58</td><td>5 (1–14)</td></tr><tr><td></td><td>T266K/N</td><td>FG</td><td>20/46</td><td></td><td>3/7</td><td>5/5</td><td>28/58</td><td>48 (35–62)</td></tr><tr><td></td><td>G268E</td><td>FG</td><td>2/46</td><td></td><td>0/7</td><td>1/5</td><td>3/58</td><td>5 (1–14)</td></tr><tr><td></td><td>K495R</td><td>Ct</td><td>14/46</td><td></td><td>3/7</td><td>1/5</td><td>18/58</td><td>31 (20–45)</td></tr><tr><td>52</td><td>Q282K</td><td>FG</td><td>15/127</td><td></td><td>0/1</td><td><bold>0/76</bold><xref rid="tblfn3" ref-type="table-fn">⁎</xref></td><td>15/205</td><td>7 (4–12)</td></tr><tr><td></td><td>K355T</td><td>HI</td><td>10/127</td><td></td><td>0/1</td><td>0/76</td><td>10/205</td><td>5 (2–9)</td></tr><tr><td></td><td>S358D/N</td><td>HI</td><td>14/127</td><td></td><td>0/1</td><td><bold>0/76</bold><xref rid="tblfn3" ref-type="table-fn">⁎</xref></td><td>14/205</td><td>7 (4–11)</td></tr><tr><td></td><td>D448E</td><td>α4-βJ</td><td>13/127</td><td></td><td>0/1</td><td><bold>0/76</bold><xref rid="tblfn3" ref-type="table-fn">⁎</xref></td><td>13/205</td><td>6 (3–11)</td></tr><tr><td>58</td><td>V118I</td><td>DE</td><td>15/75</td><td>2/31</td><td><bold>46/81</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td><bold>9/278</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td>72/465</td><td>15 (12–19)</td></tr><tr><td></td><td>L124F</td><td>DE</td><td>61/75</td><td>29/31</td><td><bold>38/81</bold><xref rid="tblfn3" ref-type="table-fn">⁎</xref></td><td>205/278</td><td>333/465</td><td>72 (67–76)</td></tr><tr><td></td><td>S133G</td><td>DE</td><td>8/75</td><td>1/31</td><td><bold>32/81</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td><bold>4/278</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td>45/465</td><td>10 (7–13)</td></tr><tr><td></td><td>P137T</td><td>DE</td><td>8/75</td><td>1/31</td><td><bold>30/81</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td><bold>4/278</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td>43/465</td><td>9 (7–12)</td></tr><tr><td></td><td>K266T/N</td><td>FG</td><td>8/75</td><td>1/31</td><td><bold>30/81</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td><bold>4/278</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td>43/465</td><td>9 (7–12)</td></tr><tr><td></td><td>A270P</td><td>FG</td><td>8/75</td><td>1/31</td><td><bold>30/81</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td><bold>4/278</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td>43/465</td><td>9 (7–12)</td></tr><tr><td></td><td>D273N</td><td>FG</td><td>8/75</td><td>1/31</td><td><bold>30/81</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td><bold>3/278</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td>42/465</td><td>9 (7–12)</td></tr><tr><td></td><td>V285G/A</td><td>FG</td><td>9/75</td><td>1/31</td><td><bold>34/81</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td><bold>7/278</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td>51/465</td><td>11 (8–14)</td></tr><tr><td></td><td>I299M/L</td><td>βG1</td><td>62/75</td><td>28/31</td><td><bold>38/81</bold><xref rid="tblfn3" ref-type="table-fn">⁎</xref></td><td>211/278</td><td>339/465</td><td>73 (69–77)</td></tr><tr><td></td><td>T349N</td><td>HI</td><td>1/75<xref rid="tblfn3" ref-type="table-fn">⁎</xref></td><td>2/31</td><td>11/81</td><td>26/278</td><td>40/465</td><td>9 (6–12)</td></tr><tr><td></td><td>G352D</td><td>HI</td><td>8/75</td><td>1/31</td><td><bold>30/81</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td><bold>4/278</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td>43/465</td><td>9 (7–12)</td></tr><tr><td></td><td>D357N</td><td>HI</td><td>8/75</td><td>1/31</td><td><bold>30/81</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td><bold>4/278</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td>43/465</td><td>9 (7–12)</td></tr><tr><td></td><td>I386V</td><td>α2</td><td>10/75</td><td>2/31</td><td><bold>46/81</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td><bold>16/278</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td>74/465</td><td>16 (13–20)</td></tr><tr><td></td><td>D394N</td><td>α2-α3</td><td>14/75</td><td>2/31</td><td><bold>45/81</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td><bold>10/278</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td>71/465</td><td>15 (12–19)</td></tr><tr><td></td><td>N396D</td><td>α3</td><td>15/75</td><td>2/31</td><td><bold>46/81</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td><bold>10/278</bold><xref rid="tblfn5" ref-type="table-fn">⁎⁎⁎</xref></td><td>73/465</td><td>16 (13–19)</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>18</td><td>L3M</td><td>Nt</td><td>3/13</td><td></td><td></td><td>1/10</td><td>4/23</td><td>17 (5–39)</td></tr><tr><td></td><td>T88N</td><td>βC-βD</td><td>10/13</td><td></td><td></td><td>3/10</td><td>13/23</td><td>57 (34–77)</td></tr><tr><td></td><td>A103V</td><td>βD</td><td>2/13</td><td></td><td></td><td>1/10</td><td>3/23</td><td>13 (3–34)</td></tr><tr><td></td><td>Q273P</td><td>FG</td><td>2/13</td><td></td><td></td><td>0/10</td><td>2/23</td><td>9 (1–28)</td></tr><tr><td></td><td>V323I</td><td>βG2-βH1</td><td>4/13</td><td></td><td></td><td>0/10</td><td>4/23</td><td>17 (5–39)</td></tr><tr><td>45</td><td>S23N</td><td>Nt-βB1</td><td>12/13</td><td></td><td></td><td></td><td>12/13</td><td>92 (64–100)</td></tr><tr><td></td><td>N55S</td><td>BC</td><td>7/13</td><td></td><td></td><td></td><td>7/13</td><td>54 (25–81)</td></tr><tr><td></td><td>I140V</td><td>DE</td><td>3/13</td><td></td><td></td><td></td><td>3/13</td><td>23 (5–54)</td></tr><tr><td></td><td>E287D</td><td>FG</td><td>1/13</td><td></td><td></td><td></td><td>1/13</td><td>8 (0–36)</td></tr><tr><td></td><td>I303T</td><td>βG1</td><td>4/13</td><td></td><td></td><td></td><td>4/13</td><td>31 (9–61)</td></tr><tr><td></td><td>N353T</td><td>HI</td><td>1/13</td><td></td><td></td><td></td><td>1/13</td><td>8 (0–36)</td></tr><tr><td></td><td>S357G/N</td><td>HI</td><td>11/13</td><td></td><td></td><td></td><td>11/13</td><td>85 (55–98)</td></tr><tr><td></td><td>Q366H</td><td>HI-βI</td><td>7/13</td><td></td><td></td><td></td><td>7/13</td><td>54 (25–81)</td></tr><tr><td></td><td>ΔT499</td><td>Ct</td><td>11/13</td><td></td><td></td><td></td><td>11/13</td><td>85 (55–98)</td></tr><tr><td></td><td>ΔA500</td><td>Ct</td><td>11/13</td><td></td><td></td><td></td><td>11/13</td><td>85 (55–98)</td></tr><tr><td></td><td>ΔS501</td><td>Ct</td><td>11/13</td><td></td><td></td><td></td><td>11/13</td><td>85 (55–98)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>a</label><p>L1 region incorporating substitutions or deletions (Δ) within amino (Nt) and carboxy (Ct) terminii, external loops (BC, DE, EF, FG, HI), alpha helices (α) or beta sheets (β).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn2"><label>b</label><p>Proportion of regional sequences harboring indicated mutation relative to total number of sequences with differences highlighted in bold type.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn3"><label>⁎</label><p><italic>p</italic><0.05; (2-tailed Fisher’s exact test).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn4"><label>⁎⁎</label><p><italic>p</italic><0.01; (2-tailed Fisher’s exact test).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn5"><label>⁎⁎⁎</label><p><italic>p</italic><0.001 (2-tailed Fisher’s exact test).</p></fn></table-wrap-foot></table-wrap></floats-group></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Ticri/CIDE/explor/EpistemeV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000119 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000119 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Ticri/CIDE
|area= EpistemeV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.31. |  |